Universitätspublikationen
Refine
Year of publication
- 2022 (403) (remove)
Document Type
- Article (341)
- Preprint (27)
- Conference Proceeding (19)
- Doctoral Thesis (16)
Language
- English (403) (remove)
Has Fulltext
- yes (403)
Is part of the Bibliography
- no (403)
Keywords
- COVID-19 (8)
- inflammation (8)
- Inflammation (6)
- Cancer (5)
- bladder cancer (5)
- data science (5)
- glioblastoma (5)
- hepatocellular carcinoma (5)
- prostate cancer (5)
- ADHD (4)
- Radiotherapy (4)
- SARS-CoV-2 (4)
- Surgery (4)
- cancer (4)
- glioma (4)
- Biomarker (3)
- Lung failure (3)
- NSCLC (3)
- artificial intelligence (3)
- chemotherapy (3)
- digital medicine (3)
- immunotherapy (3)
- machine learning (3)
- machine-learning (3)
- periodontitis (3)
- polypharmacy (3)
- radical prostatectomy (3)
- stroke (3)
- ACLF (2)
- Accidental reaction (2)
- Allergen avoidance (2)
- Anti-IgE (2)
- Attention-deficit/hyperactivity disorder (2)
- Biomedical informatics (2)
- COVID-19 surveillance (2)
- Cochlear implant (2)
- Data science (2)
- Depression (2)
- Elderly (2)
- Emotion regulation (2)
- EphB4 (2)
- Epicutaneous immunotherapy (2)
- Epigenetics (2)
- Geriatric patients (2)
- Germany (2)
- Immunology (2)
- LncRNA (2)
- MRI (2)
- Magnetic resonance imaging (2)
- Medical research (2)
- NADPH oxidase (2)
- NS5A (2)
- Omicron (2)
- Oncology (2)
- Oral immunotherapy (2)
- Penile carcinomas (2)
- Prostate cancer (2)
- RNAseq (2)
- Rectal cancer (2)
- Rheumatoid arthritis (2)
- SARS-CoV-2 monitoring (2)
- SPM (2)
- Sex (2)
- T-cell (2)
- TAVI (2)
- TIPS (2)
- Tight junctions (2)
- Translational research (2)
- Uteroglobin (2)
- antiseizure medication (2)
- aortic stenosis (2)
- autophagy (2)
- biliary stricture (2)
- brain metastases (2)
- brain metastasis (2)
- cartilage (2)
- child (2)
- cognition (2)
- complication (2)
- coronavirus (2)
- depression (2)
- diagnosis (2)
- elderly (2)
- ephrinB2 (2)
- epilepsy (2)
- functional outcome (2)
- general practice (2)
- glycolysis (2)
- growth (2)
- hyperglycemia (2)
- hypoxia (2)
- immune checkpoint inhibitors (2)
- immunity (2)
- immunohistochemistry (2)
- infection (2)
- integrins (2)
- invasion (2)
- leptin (2)
- lipoxygenase (2)
- long non-coding RNA (2)
- lung cancer (2)
- macrophage (2)
- metabolomics (2)
- microRNA (2)
- microglia (2)
- motility (2)
- multidetector computed tomography (2)
- multimorbidity (2)
- neurodegeneration (2)
- neuropathic pain (2)
- nivolumab (2)
- nociception (2)
- osteoarthritis (2)
- outcomes (2)
- overall survival (2)
- pain (2)
- pandemic (2)
- patients (2)
- pediatric surgery (2)
- primary care (2)
- process evaluation (2)
- proteomics (2)
- quality of life (2)
- radical cystectomy (2)
- resolution of inflammation (2)
- scaffold (2)
- sphingolipids (2)
- stereotactic radiosurgery (2)
- systematic review (2)
- temozolomide (2)
- thrombolysis (2)
- transcription factor (2)
- traumatic brain injury (2)
- tumor microenvironment (2)
- vaccination (2)
- 177Lu-PSMA-617 (1)
- 223Radium-dichloride (1)
- 3 mm RAS instruments (1)
- 3 mm instruments (1)
- 3-hydroxyisovaleryl carnitine (1)
- 3D culture (1)
- 3D laparoscopy (1)
- 3D-models (1)
- 3D-printing (1)
- A498 cells (1)
- ABC transporter (1)
- ACKR (1)
- ADHS (1)
- AKT-mTOR pathway (1)
- AML (1)
- ARDS (1)
- ATM (1)
- Ablation Techniques (1)
- Acinetobacter baumannii (1)
- Active middle ear implants (1)
- Activities of daily living (1)
- Acute (1)
- Acute decompensation (1)
- Acute kidney injury (1)
- Acute myeloid leukaemia (1)
- Acute-on-chronic liver failure (1)
- Affect (1)
- Aggression (1)
- Aging (1)
- Akt-mTOR pathway (1)
- Akt-mTOR signaling (1)
- Allgemeinmedizin (1)
- Ambulatory Assessment (1)
- Anaemia (1)
- Anakinra (1)
- Angiogenesis (1)
- Angiography (1)
- Animal models (1)
- Antibiotics (1)
- Antibodies (1)
- Antigen test (1)
- Aortic stenosis (1)
- Aperiodic (1)
- Apoptosis (1)
- Arteria ophthalmica (1)
- Aspergillus (1)
- Ataxia (1)
- Atrial fibrillation classification (1)
- Attentional bias (1)
- Auditory system (1)
- Autoimmunity (1)
- Autophagy (1)
- Autopsy (1)
- Ayahuasca (1)
- B.1.1.529 (1)
- BA.4 (1)
- BA.5 (1)
- BET proteins (1)
- BH3 mimetics (1)
- BMNC (1)
- BMP4 (1)
- BNT162b2 (1)
- Bacillus subtilis (1)
- Bacteraemia (1)
- Bacteria (1)
- Balance (1)
- Bartonella adhesin A (1)
- Behavioral tests (1)
- Bentall operation (1)
- Biceps brachii (1)
- Bilateral sagittal split osteotomy (1)
- Biological sciences (1)
- Bipolar disorder (1)
- Blindness (1)
- Blood loss (1)
- Blood pressure (1)
- Blood sample handling (1)
- Bloodstream infections (1)
- Body modification (1)
- Bone conduction devices (1)
- Bone dust (1)
- Bone marrow aspiration (1)
- Brachytherapy (1)
- Brain (1)
- Brain tumor (1)
- Brodalumab (1)
- Burkholderia arboris (1)
- C-reactive protein (1)
- CAR (1)
- CBC (1)
- CD4+ T cells (1)
- CD40 (1)
- CDK-cyclin axis (1)
- CHEPs (1)
- CHRDL1 (1)
- CIRS (1)
- CK2α (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- CLOCC (1)
- CNS tumor (1)
- COMP (1)
- COVID-19 epitope signatures (1)
- CQL (1)
- CRP (1)
- CRT (1)
- CT (1)
- CTGF (1)
- CXCL13 (1)
- CaMPARI (1)
- Calliphoridae (1)
- Capsaicin (1)
- Cardiac infarction (1)
- Cardiac remodeling (1)
- Cardiovascular diseases (1)
- Case report (1)
- Catheters (1)
- Cell Biology (1)
- Cell death (1)
- Cell death and immune response (1)
- Cellular network formation (1)
- Central Europe (1)
- Cerebellum (1)
- Cerebral oxygen saturation (1)
- ChAdOx1-S (1)
- Chemoradiotherapy (1)
- Chemotherapy (1)
- Chronic lymphocytic leukemia (1)
- Circulating MiRNA (1)
- Cirrhosis (1)
- Classification (1)
- Click chemistry (1)
- Clinical Trials and Observations (1)
- Clinical management (1)
- Clinical phenotype (1)
- Clinical practice guidelines (1)
- Clinical trials (1)
- Cognition (1)
- Cognitive (1)
- Colloids (1)
- Colony stimulating factor 1 receptor (1)
- Comorbidities (1)
- Comorbidity (1)
- Comparative analysis (1)
- Complete response (1)
- Completed suicide (1)
- Complex elbow fractures (1)
- Comprehensive complication index (1)
- Computer software (1)
- Concurrent CNS diseases (1)
- Congenital (1)
- Connective tissue (1)
- Consensus statement (1)
- Conventional and unconventional ubiquitination (1)
- Convolutional Neural Networks (1)
- Coronavirus (1)
- Coronaviruses (1)
- Culex pipiens biotypes pipiens/molestus (1)
- CysLTR1 (1)
- D-amino acid oxidase (1)
- DAA (1)
- DILI (1)
- DNA methylation (1)
- DNA mismatch repair (1)
- DNA-PK (1)
- DNA-based identification (1)
- DVI (1)
- DWI (1)
- Data preprocessing (1)
- Data structure detection (1)
- Deep brain stimulation (1)
- Deep neural network (1)
- Degradation (1)
- Dental students (1)
- Depression stigma (1)
- Detection workflow (1)
- Dexterity (1)
- Diagnostic imaging (1)
- Diagnostic tests (1)
- Diet (1)
- Dimethyltryptamine (1)
- Donor screening (1)
- Dot-probe task (1)
- Downgrading (1)
- Dynamic MRI (1)
- EEG (1)
- EGFR (1)
- ER stress (1)
- Elderly trauma patient (1)
- Emotional intelligence (1)
- Empathy (1)
- Endocannabinoids (1)
- Endogenous retroviruses (ERV) (1)
- Endoluminal (1)
- Endorectal (1)
- Endothelial (1)
- Endothelial-to-mesenchymal transition (1)
- Energy-efficiency (1)
- Environmental impacts (1)
- Epidemiology (1)
- Epilepsy (1)
- Erythrophagocytosis (1)
- Europe (1)
- Euthymic phase (1)
- Explicit (1)
- Extracorporeal devices (1)
- FDG-PET/CT (1)
- FFLU (1)
- FHIR (1)
- FHIR Search (1)
- FPR (1)
- Face masks (1)
- Fall (1)
- Famines (1)
- Fast Healthcare Interoperability Resources (1)
- Feasibility (1)
- Fehlerberichtssystem (1)
- Fetal heart (1)
- Fibroblast (1)
- Filgrastim (1)
- Filler (1)
- Flavin mononucleotide (1)
- Follicular lymphoma (1)
- Follow-ups (1)
- Fondaparinux (1)
- Fracture models (1)
- Frameshift (1)
- Fruit fly (1)
- Functional electrical stimulation (1)
- Functional outcomes (1)
- Funktionelle Bildgebung (1)
- G3BP1 (1)
- GDF11 (1)
- GEMs (1)
- GPCR (1)
- GRAND-SLAM (1)
- GSH (1)
- GVL (1)
- Gene (1)
- Gene expression (1)
- Gene sequencing (1)
- Genetic loci (1)
- Genetic networks (1)
- Genetics (1)
- Genetics research (1)
- Geschlecht (1)
- Glabella (1)
- Gleason Grade group (1)
- Glioblastoma (1)
- Glioma (1)
- Gradient boosting (1)
- Groin pain (1)
- Gut bacteria (1)
- GvL (1)
- HCV (1)
- HEOR (1)
- HES (1)
- HIF (1)
- HIF-1α (1)
- HIF-2α (1)
- HIF-2α, erythropoietin (1)
- HIPPO signalling (1)
- HL7 FHIR (1)
- HNSCC (1)
- HPV infection (1)
- HSCT (1)
- Haemodialysis (1)
- Hardware erosion (1)
- Head neck cancer (1)
- Health policy (1)
- Health sciences (1)
- Healthcare (1)
- Healthy stem cell donors (1)
- Heart (1)
- Heart defects (1)
- Heart rate (1)
- Hematoma (1)
- Hematopoietic stem cell transplant (1)
- Hemosiderin (1)
- Hepatitis C (1)
- Hepatitis C antibodies (1)
- Hepatitis C antigens (1)
- Hepatotoxicity (1)
- Heterologous prime-boost (1)
- High oblique sagittal osteotomy (1)
- Hip revision (1)
- HoLEP (1)
- Hodgkin lymphoma (1)
- Holmium laser enucleation (1)
- Home Care Services [MeSH] (1)
- Human chorionic villi mesenchymal stromal cells (1)
- Human retroelements (1)
- Human visual cortex (1)
- Hydroxyethyl starch (1)
- Hypertension (1)
- Hypertensive disorders in pregnancy (1)
- IGF-1 (1)
- IL-17 (1)
- IR (1)
- Idelalisib (1)
- Identification (1)
- Identifier (1)
- Immunity (1)
- Immunoassay (1)
- Immunogenicity (1)
- Immunotherapy (1)
- Implicit (1)
- Impoverishment (1)
- Impulse generator (1)
- In-TIPS thrombosis (1)
- Incident reporting system (1)
- Incidental prostate cancer (1)
- Induction therapy (1)
- Inequality (1)
- Inguinal hernia (1)
- Inguinal pain (1)
- Inherited arrhythmic syndrome (1)
- Integrative Network Analysis (1)
- Interaction (1)
- Interleukin-1 (1)
- Intermediate-risk (1)
- Intraoperative procedure (1)
- Intravenous iron (1)
- Iron deficiency (1)
- Isoforms (1)
- Jaw surgery (1)
- Jurkat (1)
- Kidneys (1)
- Knee joint sound (1)
- Knee osteoarthritis (1)
- Knees (1)
- LAMTOR1 (1)
- LASS (1)
- LC-MS-based lipid mediator analysis (1)
- LCD-Array (1)
- Large vessel occlusion (1)
- Lee-type (1)
- Legionella pneumophila (1)
- Legs (1)
- Ligand post-insertion (1)
- Lipid peroxidation (1)
- Liver (1)
- Liver Fibrosis (1)
- Local therapy (1)
- Long interspersed nuclear elements (LINE) (1)
- Long-term follow-up (1)
- Long-term results (1)
- Low-molecular-weight heparin (1)
- MAP kinase (1)
- MEN1 (1)
- MGMT (1)
- MGMT promoter (1)
- MLH1 (1)
- MMPs (1)
- MUTARS® RS Cup System (1)
- MUTARS® RS cup system (1)
- Machine learning (1)
- Machine-learning (1)
- Maintenance therapy (1)
- Major depressive disorder (1)
- Malignancy (1)
- Malnutrition (1)
- Masquelet technique (1)
- Mathematical biosciences (1)
- Medical Oncology (1)
- Mental disorder (1)
- Metabolism (1)
- Metabolomics (1)
- Metastasis (1)
- Methylation (1)
- MiR-29 (1)
- Microbiology, Virology & Host Pathogen Interaction (1)
- Microbiome (1)
- Microenvironment (1)
- Microglia (1)
- Microplastic (1)
- Mild hypoxia (1)
- Mini-monovision (1)
- Mitochondria (1)
- Mitochondrial complex I (1)
- Mixed hearing loss (1)
- Model organisms (1)
- Molecular autopsy (1)
- Molecular matched therapy (1)
- Molecular mimicry (1)
- Molecular profiling (1)
- Monocyte gene expression (1)
- Mood (1)
- Morphology (1)
- Mortality (1)
- Motility (1)
- Mouse (1)
- Mouse models (1)
- Multi-stakeholder approach (1)
- Multi-syndrome classification (1)
- Multiple sclerosis (1)
- Muscle (1)
- Muscle analysis (1)
- Muscle damage (1)
- Muscle pain (1)
- Myeloid Neoplasia (1)
- Myocardial infarction (1)
- Myocarditis (1)
- NASH (1)
- NIS (1)
- NR4A2 (1)
- NR4A3 (1)
- NVBP (1)
- Nanoplastic (1)
- Needs Assessment [MeSH] (1)
- Neurodegenerative syndromes (1)
- Neurodevelopmental disorder (1)
- Neuromuscular exercise (1)
- Neuroscience (1)
- Nkx2-5 (1)
- Non-diffractive EDOF-IOL (1)
- Nonoperative management (1)
- Nox (1)
- Nox inhibition (1)
- Nrf2 (1)
- Obesity (1)
- Observational (1)
- Occlusion (1)
- Older patients (1)
- Omicron variant BA.1 (1)
- One-leg stand (1)
- Online education (1)
- Ophthalmoplegia (1)
- Optical phenomena (1)
- Organ preservation (1)
- Orthognathic surgery (1)
- Orthopaedics (1)
- Oscillating saws (1)
- Outcome (1)
- PBBM (1)
- PCR (1)
- PD-L1 (1)
- PDPK1 (1)
- PI3K (1)
- PI3K inhibitor (1)
- PLGA (1)
- PMI (1)
- PPTC7 (1)
- PRG5 (1)
- PSMA (1)
- PTEN (1)
- PacBio SMRT sequencing (1)
- Paediatric cancer (1)
- Palliative Care [MeSH] (1)
- Pandemic (1)
- Papillon-Lefèvre syndrome (1)
- Parkinson’s disease (1)
- Particle load reduction (1)
- Particle size distribution (1)
- Particle toxicity (1)
- Particulate matter (1)
- Patient Outcome Assessment [MeSH] (1)
- Patient Reported Outcome Measures [MeSH] (1)
- Patient care (1)
- Patient safety (1)
- Perceived stigma (1)
- Periodic (1)
- Peripheral blood smears (1)
- Personal stigma (1)
- Personality inventory (1)
- Phagocytosis (1)
- Physical activity (1)
- Physical and mental health (1)
- Physics (1)
- Placental organoids (1)
- Plasma (1)
- Plastic pollution (1)
- Plasticity (1)
- Plastics (1)
- Polytrauma (1)
- Portuguese population (1)
- Positron emission tomography (1)
- Post-mortem genetic screening (1)
- Postural control (1)
- Postural sway (1)
- Pre-analytics (1)
- Pre-operative radiotherapy (1)
- Precision medicine (1)
- Preclinical research (1)
- Predictive markers (1)
- Predominant polarity (1)
- Preeclampsia (1)
- Presbyopia (1)
- Primary cilium (1)
- Propensity score matching (1)
- Protein (1)
- Protocol (1)
- Pseudomonas aeruginosa (1)
- Psychedelics (1)
- Psychiatric traits (1)
- Purdue Pegboard (1)
- Qualitative Research [MeSH] (1)
- Quality of Health Care [MeSH] (1)
- Quality of life (1)
- Quantitative Imaging (1)
- Quarantine (1)
- RAS (1)
- RCC (1)
- RCT (1)
- RESLES (1)
- RNA (1)
- RNA stability (1)
- RNA therapeutics (1)
- RNA turnover (1)
- RNA virus (1)
- RUCAM (1)
- Rab7 (1)
- Radical prostatectomy (1)
- Ragulator complex (1)
- Random forest (1)
- Randomized controlled trials (1)
- Reactogenicity (1)
- Real world study (1)
- Refractive lense exchange (1)
- Registry (1)
- Rehabilitation (1)
- Relapse surveillance (1)
- Research data (1)
- Research patterns (1)
- Research validity (1)
- Resilience (1)
- Reverse electron transfer (1)
- Rhabdomyosarcoma (1)
- Ribosomal RNA (1)
- Risk assessment (1)
- Rodents (1)
- Roussel Uclaf Causality Assessment Method (1)
- Routinely Collected Health Data [MeSH] (1)
- S1P (1)
- S1P receptors (1)
- S1P5 (1)
- S1PR5 (1)
- SARS coronavirus (1)
- SARS-CoV-2 testing (1)
- SARS-CoV-2-specific T cells (1)
- SARS-CoV2 (1)
- SF-12 (1)
- SLAM-seq (1)
- SMOC1 (1)
- SOD (1)
- SSTI (1)
- STAT3 (1)
- SUDEP (1)
- Safety culture (1)
- Sanger Sequencing (1)
- Sarcophagidae (1)
- Scalp defect (1)
- Scheduling of radiotherapy (1)
- Schizophrenia (1)
- Screening (1)
- Self-renewal (1)
- Sequelae (1)
- Serology (1)
- Serum (1)
- Siderosis (1)
- Single positive core biopsy (1)
- Skeletal muscles (1)
- Sodium chloride (1)
- Soft tissue sarcoma (1)
- Sphk1 (1)
- Sphk2 (1)
- Sports and exercise medicine (1)
- Statin (1)
- Stigma scale (1)
- Stoppa approach (1)
- Stroke (1)
- Stroke unit (1)
- Subjective effects (1)
- Sudden cardiac death (1)
- Sudden death (1)
- Suicide (1)
- Suicide attempt (1)
- Superficial vein thrombosis (1)
- Support vector machine (1)
- Surgical oncology (1)
- Synapse (1)
- Synovial sarcoma (1)
- Systems & Computational Biology (1)
- T helper cell differentiation (1)
- TBI (1)
- TIRADS (1)
- TOR signalling (1)
- TTW nodules (1)
- TUR-P (1)
- Targeted delivery (1)
- Targeted therapies (1)
- Targeted therapy (1)
- Tattoo (1)
- Teaching (1)
- Technical data (1)
- Temozolomide (1)
- Therapy (1)
- Thoracic trauma (1)
- Tissue expander (1)
- Tissue microarray (1)
- Tissue-specificity (1)
- Total elbow arthroplasty (1)
- Toxicity (1)
- Training (1)
- Transfusion (1)
- Transitional fractures 3D printing (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transjugular intrahepatic portosystemic shunt (1)
- Transurethral resection of the prostate (1)
- Trauma (1)
- Trauma centre (1)
- TraumaRegister DGU® (1)
- Traumatic brain injury (1)
- Traumatology (1)
- Travel regulations (1)
- Treatment (1)
- Treatment management (1)
- Treatment response (1)
- Truncating mutation (1)
- Truncus arteriosus (1)
- Tumor microenvironment (1)
- Tumour immunology (1)
- UGCG (1)
- UPR (1)
- USP28 (1)
- USP32 (1)
- Ultrasound (1)
- Undergraduate (1)
- Upgrading (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Urine (1)
- Urological oncology (1)
- V4 (1)
- VUS (1)
- Vaccination (1)
- Valvular cardiomyopathy (1)
- Variant of concern (1)
- Vasculitis (1)
- Venous thrombosis (1)
- Vibroarthrography (1)
- Viral hepatitis (1)
- Viral infection (1)
- Viral oncology (1)
- Virological testing (1)
- Visual-field localizer (1)
- Volume therapy (1)
- Von Hippel–Landau (1)
- Wastewater-based epidemiology (WBE) (1)
- Zebrafish (1)
- Zuckerkandl’s tubercle (1)
- aGVHD (1)
- acarboxyprothrombin (1)
- acetabular fracture (1)
- acute and chronic graft versus host disease (a/c GVHD) (1)
- acute infections (1)
- acute lymphoblastic leukemia (1)
- acute respiratory distress syndrome (1)
- acute stroke (1)
- acute-on-chronic liver failure (1)
- additive manufacturing (1)
- adipose-derived stromal/stem cells (1)
- adjuvant chemotherapy (1)
- adolescents (1)
- age (1)
- aging (1)
- albumin (1)
- alcohol (1)
- algorithm (1)
- aligners (1)
- allogeneic hematopoietic stem cell transplantation (aHSCT) (1)
- alpha-fetoprotein (1)
- alphaSynuclein (1)
- alteplase (1)
- alternative splicing (1)
- alveolar ridge augmentation (1)
- amino acids (1)
- amygdalin (1)
- anaplastic large cell lymphoma (1)
- anemia (1)
- anesthesia (1)
- angiogenesis (1)
- animal model (1)
- anorexia nervosa (1)
- anti-EGFR therapy (1)
- anti-bacterial agents (1)
- anti-inflammatory agent (1)
- antiangiogenic therapy (1)
- antiangiogenic therapy resistance (1)
- antioxidant (1)
- antiviral agents (1)
- apex (1)
- arachidonic acid (1)
- arthritis (1)
- articular chondrocytes (1)
- asparaginyl endopepdidase (AEP) (1)
- atezolizumab (1)
- attachment loss (1)
- attention (1)
- atypical EGFR mutations (1)
- autophagy-dependent cell death (1)
- awake surgery (1)
- benchmarking (1)
- beta2-adrenoceptor (1)
- bevacizumab (1)
- biofilm (1)
- bioimaging (1)
- bioinformatics (1)
- biomarker (1)
- biomarkers (1)
- biorelevant dissolution (1)
- biotin deficiency (1)
- bone (1)
- bone marrow microenvironment (1)
- bone metastasis (1)
- bone regeneration (1)
- bone tissue engineering (1)
- bowel management (1)
- breast cancer (1)
- breast tumor (1)
- bromodomain and extraterminal (BET) protein (1)
- bronchial epithelium (1)
- bulimia nervosa (1)
- buparlisib (1)
- burden of illness (1)
- burkholderia (1)
- burkholderia cepacia complex infections (1)
- c-MYC (1)
- cabazitaxel (1)
- cabozantinib (1)
- cardiac remodeling (1)
- cardiovascular system (1)
- caregivers (1)
- casein kinase 2 (1)
- cataract surgery (1)
- cataract surgery workflow (1)
- cell therapy (1)
- cellular heterogeneity (1)
- cellular inflammatory response (1)
- ceramide synthase (1)
- cerebral pseudoprogression (1)
- cerebral vasospasm (CVS) (1)
- cerebrovascular disease (1)
- chemoradiotherapy (1)
- chemorefractory metastatic colorectal cancer (1)
- children (1)
- chimeric antigen receptor (CAR) (1)
- chromaffin cell (1)
- chronic hypoxia (1)
- chronic infections (1)
- cirrhosis (1)
- cisplatin (1)
- clear cell renal cell carcinoma (1)
- clear cell sarcoma (1)
- clear lens exchange (1)
- climate change genomics (1)
- clinical decision support (1)
- clinical isolates (1)
- clinical outcome (1)
- clinical study (1)
- clinically relevant dissolution specifications (1)
- clonal transfer (1)
- co-infection (1)
- cognitive impairment (CI) (1)
- colon (1)
- colony formation (1)
- colorectal cancer (1)
- colorectal cancer (CRC) (1)
- colorectal cancer liver metastases (CRLM) (1)
- complementary medicine (1)
- complementary/alternative medicine (CAM) (1)
- computational pathology (1)
- confinement (1)
- congenital duodenal obstruction (1)
- consensus classification (1)
- consensus data set (1)
- constipation (1)
- continuity of care (1)
- conventional/traditional transarterial chemoembolization (cTACE) (1)
- copper free strain-promoted azide alkyne cycloaddition (SPAAC) (1)
- cord clamping (1)
- corpus callosum (1)
- cortex-based alignment (1)
- cortical impact (1)
- corticospinal tracts (1)
- cost analysis (1)
- cost containment (1)
- cost of illness (1)
- counseling (1)
- counselling (1)
- critical care (1)
- critical size defect (1)
- cryopreservation (1)
- cystic fibrosis (1)
- cytochrome c oxidase I (COI) (1)
- cytokine(s) (1)
- cytosolic free calcium (1)
- data analysis (1)
- data management (1)
- de novo transcription (1)
- decision tree (1)
- deep learning (1)
- delay (1)
- delayed cerebral ischemia (DCI) (1)
- dendritic cell (1)
- dental academic degrees (1)
- dental educationcation (1)
- dental implant (1)
- dental implants (1)
- deproteinized bovine bone matrix (DBBM) (1)
- detection task (1)
- deubiquitinase (DUB) (1)
- diabetes (1)
- diagnostic imaging (1)
- differential expression (1)
- diffusion-weighted magnetic resonance imaging (1)
- digital decision-support (1)
- disease outbreaks (1)
- disease vectors (1)
- distributed analysis (1)
- docetaxel (1)
- doctoral degrees (1)
- dopamine (1)
- double negative (1)
- double-pigtail stents (1)
- drug-eluting beads TACE (DEB-TACE) (1)
- drug-induced liver injury (1)
- dysphagia (1)
- eating disorders (1)
- economic burden (1)
- education (1)
- efficiency (1)
- eicosanoid (1)
- electron transfer chain (1)
- electronic diaries (1)
- electrophoresis (1)
- enamel matrix derivatives (1)
- encephalopathy (1)
- endoscopic retrograde cholangiography (1)
- endothelial cells (1)
- endovascular recanalization (1)
- endovascular thrombectomy (1)
- endovascular treatment (1)
- ensemble cNN (1)
- environmental tobacco smoke (1)
- epidural (1)
- epoxyeicosatrienoic acid (1)
- erectile dysfunction (1)
- ergonomics (1)
- everyday tasks (1)
- evidence-based guideline (1)
- exosome (1)
- extracellular vesicles (1)
- eye tracking (ET) (1)
- fMRI (1)
- fall (1)
- familial amyloid nephropathy with urticaria and deafness (1)
- fat pad resection (1)
- feasibility study (1)
- federated feasibility queries (1)
- fibrin-glue-spray technique (1)
- fibrosis (1)
- flow cytometry (1)
- fluorescence in situ hybridization (FISH) (1)
- focal therapy (1)
- foreign body reaction (1)
- fragment screening (1)
- fragment-size analyses (ACE2; CQ11) (1)
- fungal sinusitis (1)
- gangliosides (1)
- gasotransmitters (1)
- gefitinib (1)
- gel (1)
- gene expression (1)
- gene signature (1)
- gene therapy (1)
- general practitioners (1)
- genetic variability (1)
- genome (1)
- glioblastoma survival (1)
- glioma stem-like cells (1)
- globosides (1)
- glomerulus (1)
- glucose and lipid metabolism (1)
- glucosylceramide (1)
- gravity (1)
- guided bone regeneration (1)
- guided tissue regeneration (1)
- habitat (1)
- haemophilia treatment (1)
- head and neck squamous cell carcinoma (1)
- health behavior (1)
- health care (1)
- health data (1)
- health education (1)
- health services research (1)
- health-related quality of life (1)
- healthcare system (1)
- heart failure (1)
- heart neoplasms (1)
- hematopoietic stem cell transplantation (1)
- hemorrhage (1)
- hemorrhagic transformation (1)
- hepatitis B (1)
- hepatitis B surface antigen (1)
- hepatitis C virus (1)
- hepatitis D (1)
- hernia to the cord (1)
- hidradenitis suppurativa (1)
- hierarchical clustering (1)
- high throughput screening (1)
- high-content screen (1)
- hippocampal sclerosis (1)
- histology (1)
- home training (1)
- hospital length of stay (1)
- host matrix- pathogen interaction (1)
- human MSCs (1)
- human monoclonal antibody (1)
- human research (1)
- human-liver chimeric mouse model (1)
- hybrids (1)
- hydrogen sulfide (H2S) (1)
- hyperactivity (1)
- hypertrophy (1)
- hypnotics and sedatives (1)
- hypoxia-inducible factor-2α (1)
- immune checkpoint inhibitors (ICI) (1)
- immune monitoring (1)
- immune related adverse events (irAE) (1)
- immune therapy (1)
- immune-mediated inflammatory diseases (1)
- immunosenescence (1)
- inborn errors of immunity (1)
- indoor air (1)
- inertial motion capture (1)
- inertial sensors (1)
- infections (1)
- inflammatory bowel disease (1)
- infrapatellar fat pad (1)
- inguinal hernia (1)
- instructional film and video (1)
- insulin sensitivity (1)
- integrative medicine (1)
- interactions (1)
- interferon induction (1)
- interferon sensitivity (1)
- internet (1)
- intestinal obstruction (1)
- intracellular multiplication (1)
- intrahepatic cholangiocarcinoma (1)
- intraoral scanning (1)
- invasive fungal infection (1)
- irinotecan-loaded drug-eluting beads TACE (DEBIRI-TACE) (1)
- keratinized mucosa (1)
- kidney function (1)
- kinematic analysis (1)
- knee osteoarthritis (1)
- lacto/neo-lacto series GSLs (1)
- laparoscopic inguinal hernia repair (1)
- laser-induced thermotherapy (1)
- latent factor mixed model (1)
- legumain (1)
- length of stay (1)
- leukaemia (1)
- leukotriene (1)
- lipidomics (1)
- lipids (1)
- lipoxin (1)
- lipoxygenase inhibitor (1)
- liver (1)
- liver fibrosis (1)
- liver transplantation (1)
- local antibiotics (1)
- lockdown (1)
- long-term results (1)
- low-glycaemic meal replacement (1)
- lppr5 (1)
- lung tumor heterogeneity (1)
- lysophospholipids (1)
- lysosomal-dependent cell death (1)
- lysosome (1)
- mCRPC (1)
- mRNA (1)
- mTOR (1)
- mTORC1 (1)
- macaque (1)
- macrophage polarization (1)
- magnetic resonance imaging (1)
- mappers (1)
- mapping-algorithms (1)
- mechanical accuracy (1)
- mechanical recanalization (1)
- mechanical ventilation (1)
- medical device (1)
- medical informatics (1)
- medication management (1)
- medication review (1)
- melanoma (1)
- membrane remodeling (1)
- membranous urethra (1)
- mesangial cells (1)
- mesenchymal stromal/stem cells (1)
- metabolism (1)
- metastases (1)
- metastasis (1)
- metastatic prostate cancer (1)
- miR (1)
- microbial colonization (1)
- microbiology (1)
- microbiome (1)
- microlaparoscopy (1)
- microstimulation (1)
- microwave ablation (1)
- mid-term urinary continence (1)
- mineralization (1)
- minimal invasive (1)
- minimally invasive surgery (1)
- mitochondria (1)
- mixed infection (1)
- model builder software (1)
- modelling (1)
- molecular diagnostic techniques (1)
- molecular pathology (1)
- molecular subtyping (1)
- molecular typing (1)
- monitoring (1)
- monocytes (1)
- mortality (1)
- mouthwash (1)
- mouthwash solution (1)
- multicentre study (1)
- multidrug resistance (1)
- multidrug resistance protein 4 (1)
- multiparametric magnetic resonance imaging (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- multiplex immunohistochemistry (1)
- multiplexed immunofluorescence (1)
- multispectral flow cytometry (1)
- musculoskeletal disorders (1)
- neoadjuvant chemoradiotherapy (1)
- neoadjuvant chemotherapy (1)
- neoadjuvant immunochemotherapy (1)
- neoplasm metastasis (1)
- nephropathy (1)
- nerve-sparing surgery (1)
- neuroblast (1)
- neurocognition (1)
- neurocognitive outcome (1)
- neurocritical care (1)
- neuroendocrine (1)
- neurological complication (1)
- neurological side effects (1)
- neurooncology (1)
- neuropathy (1)
- neurysmal subarachnoid hemorrhage (aSAH) (1)
- neutralization (1)
- neutropenia (1)
- neutrophil elastase (1)
- newborn (1)
- newly diagnosed glioblastoma (1)
- nitric oxide (1)
- noise (1)
- non-neutropenic episode (1)
- non-organ confined stage (1)
- non-small-cell lung cancer (1)
- non-surgical periodontal therapy (1)
- nonsense-mediated mRNA decay (1)
- normal liver cells (1)
- novel technologies (1)
- nuclear receptor (1)
- nuclear receptor-related 1 (1)
- obstetric pain (1)
- obstetrics (1)
- oedema (1)
- olfaction (1)
- olfactory testing (1)
- olive mill wastewater (OMWW) (1)
- omphalocele (1)
- open (1)
- oral cavity cancer (1)
- oral drug products (1)
- osteoblast (1)
- osteoclasts (1)
- osteogenic differentiation (1)
- outbreak (1)
- outcome (1)
- outpatient care (1)
- outpatients (1)
- overall survival (OS) (1)
- oxidative phosphorylation (1)
- p16 (1)
- pain management (1)
- parabolic flight (1)
- passive smoke (1)
- pathogenicity (1)
- patient centered care (1)
- patient data (1)
- patient-centred care (1)
- patient-reported outcomes (1)
- pediatric robotic surgery (1)
- pembrolizumab (1)
- percutaneous thermal ablation (1)
- peri-implant diseases (1)
- peri-implantitis (1)
- periodontal– systemic disease interactions (1)
- perioperative mortality (1)
- peripheral injury (1)
- phantom study (1)
- pharmacophore model (1)
- phase I (1)
- phosphatidylethanolamines (1)
- phospholipid (1)
- phosphorylation (1)
- physical activity (1)
- physical performance (1)
- pimozide (1)
- platelet count (1)
- platinum-based chemotherapy (1)
- plppr5 (1)
- pole concept of goiter growth (1)
- portal hypertension (1)
- portal vein (1)
- posterior horn (1)
- posteroinferior horn (1)
- postgraduate edu (1)
- postnatal care (1)
- postoperative pain (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- precision medicine (1)
- prediction (1)
- predictive (1)
- predictive biomarker (1)
- predictor (1)
- prenatal diagnostic (1)
- prevention (1)
- preventive health services (1)
- primary health care (1)
- print and press (1)
- private brands (1)
- product performance (1)
- professional soccer players (1)
- prognosis (1)
- prognostic (1)
- progression-free survival (PFS) (1)
- prone position (1)
- propensity score matching (1)
- prostaglandin (1)
- prostaglandins (1)
- prostate neoplasia (1)
- prostatectomy (1)
- proteasomal processing escape (1)
- proteasome (1)
- protein-rich (1)
- prothrombin induced by vitamin K absence-II (1)
- psoriasis (1)
- psoriatic (1)
- pulmonary embolism (1)
- pulmonary failure (1)
- pulmonary ventilation (1)
- pulsed-field (1)
- purification (1)
- qualitative research (1)
- query (1)
- race/ethnicity disparities (1)
- radiation (1)
- radiotherapy (1)
- range expansion (1)
- rat model (1)
- rats (1)
- re-exposure (1)
- reactive oxygen species (1)
- real world (1)
- realist synthesis (1)
- rechallenge (1)
- recurrence pattern (1)
- recurrent cholangitis (1)
- refractive lens exchange (1)
- refractive surgery (1)
- reintroduction (1)
- renal fibroblasts (1)
- renal inflammation (1)
- resistant cell lines (1)
- resolvin (1)
- respiratory failure (1)
- respiratory infections (1)
- resveratrol (1)
- rheumatoid (1)
- rheumatoid arthritis (1)
- rhinovirus (1)
- rifampin (1)
- risk assessment (1)
- risk of malignancy (1)
- robot-guided stereotaxy (1)
- robotic-assisted (1)
- robotically assisted surgery (1)
- robotics (1)
- seasonal adaption (1)
- seizure (1)
- seizures (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- shape (1)
- short-course antibiotic therapy (1)
- siRNA lipid nanoparticles (LNPs) (1)
- single-cell RNA sequencing (1)
- single-cell proteomics (1)
- sleep quality (1)
- smoking behavior (1)
- social recognition (1)
- soft tissue (1)
- sound localization (1)
- speech and language pathologist (1)
- speech perception (1)
- sphingosine (1)
- sphingosine 1-phosphate (1)
- sphingosine 1-phosphate homologues (1)
- sphingosine-1-phosphate (1)
- spinal metastasis (1)
- stairs (1)
- stakeholder analysis (1)
- statistics (1)
- stent patency (1)
- stereotactic frame (1)
- stereotactic neurosurgery (1)
- stomach neoplasms (1)
- store brands (1)
- study protocol (1)
- subchondral bone (1)
- subdural hematoma (1)
- sulfatides (1)
- sunitinib (1)
- surgical procedures (1)
- survival (1)
- swarming (1)
- sympathetic (1)
- synovium (1)
- taller-than-wide (1)
- targeted therapy (1)
- temporal lobe epilepsy (1)
- theory of mind (1)
- therapeutic anticoagulation (1)
- therapeutics (1)
- thrombin (1)
- thrombocytopenia (1)
- thrombocytosis (1)
- thrombosis (1)
- thrombospondins (1)
- thromboxane (1)
- tight junctions (1)
- tissue engineering (1)
- tooth loss (1)
- tooth transplantation (1)
- toric intraocular lens (1)
- total knee replacement (1)
- trans (1)
- transcription factors (1)
- transcriptional cyclin-dependent kinase (1)
- transcriptomics (1)
- translatomics (1)
- trauma (1)
- treatment centres (1)
- triglycerides (1)
- trimeric autotransporters adhesin (1)
- tumor (1)
- tumor growth (1)
- ubiquitin (1)
- unmethylated MGMT (1)
- upgrading (1)
- upstaging (1)
- urachal cancer (1)
- urethral stricture (1)
- urinary incontinence (1)
- urothelial carcinoma (1)
- v-ATPase (1)
- variant of concern (1)
- vascular integrity (1)
- vemurafenib (1)
- viral replication (1)
- virologic failure (1)
- visual cortex (1)
- visual search (VS) (1)
- wastewater-based epidemiology (WBE) (1)
- weight reduction (1)
- whole genome pooled sequencing (1)
- workflow development (1)
- yellow fever mosquito (1)
Institute
- Medizin (403) (remove)
Gait analysis as a clinical examination method has been increasingly used in recent years. In particular, the external knee adduction moment was often used as a surrogate measure for internal medial knee joint loading, e.g., in elderly individuals with medial knee osteoarthritis. Therefore, the knee adduction moment is also associated with the progression of knee osteoarthritis. Children and adolescents with valgus malalignment have been found to experience a reduced external knee adduction moment, but internal knee joint contact forces, particularly in the lateral compartment, were not previously studied.
First, medial and lateral knee joint contact forces were studied using muskulosceletal modeling in young individuals with and without valgus malalignment treated by guided growth. In addition, a systematic literature review was conducted to explore the relationship between external joint moments and internal joint contact forces. Finally, this relationship was investigated in children and adolescents with and without valgus malalignment. Furthermore, we examined whether statistical models could be determined to accurately predict internal knee joint contact forces by commonly used parameters from three-dimensional gait analysis, such as external knee joint moments.
It was found that guided growth normalized knee joint contact forces after treatment. In addition, the static radiographic mechanical axis angle correlated better after the treatment when the patients showed a typical limb alignment compared to the correlation before guided growth with the valgus malalignment due to compensating strategies during gait. Furthermore, the systematic review showed that the peak medial knee joint contact force was best predicted by the knee adduction moment and even better together with the knee flexion moment in the first half of stance. However, for the second half of stance of the medial knee joint contact force and the entire stance of the lateral knee joint contact force, only low correlations with knee adduction and/or flexion moment were found. Finally, statistical models could be determined with high accuracy for both medial and lateral knee joint contact force, for both peaks in the first and second half of stance, and for both study groups of children and adolescents with and without valgus malalignment by including knee adduction and flexion moment as predictors.
These results demonstrate the importance of examining not only the external knee adduction moment but also the knee flexion moment and, even better, the medial and lateral knee joint contact forces when evaluating knee joint loading. With these statistical models, clinicians can predict the medial and lateral knee joint contact forces without the need to perform musculoskeletal simulations and can therefore use standard three-dimensional gait analysis parameters such as knee adduction and flexion moment. This can improve guided growth treatment in children and adolescents with valgus malalignment with regard to implantation or explantation of the growth restricting plates or to rebound. Instrumented gait analysis could be particularly helpful in borderline cases, as kinematic compensation mechanisms during gait may play a role and the static radiograph alone does not provide information about dynamic joint loads.
Erythropoietin (Epo) is a crucial hormone regulating red blood cell number and consequently the hematocrit. Epo is mainly produced in the kidney by interstitial fibroblast-like cells. Previously, we have shown that in cultures of the immortalized mouse renal fibroblast-like cell line FAIK F3-5, sphingosine 1-phosphate (S1P), by activating S1P1 and S1P3 receptors, can stabilize hypoxia-inducible factor (HIF)-2α and upregulate Epo mRNA and protein synthesis. In this study, we have addressed the role of intracellular iS1P derived from sphingosine kinases (Sphk) 1 and 2 on Epo synthesis in F3-5 cells and in mouse primary cultures of renal fibroblasts. We show that stable knockdown of Sphk2 in F3-5 cells increases HIF-2α protein and Epo mRNA and protein levels, while Sphk1 knockdown leads to a reduction of hypoxia-stimulated HIF-2α and Epo protein. A similar effect was obtained using primary cultures of renal fibroblasts isolated from wildtype mice, Sphk1−/−, or Sphk2−/− mice. Furthermore, selective Sphk2 inhibitors mimicked the effect of genetic Sphk2 depletion and also upregulated HIF-2α and Epo protein levels. The combined blockade of Sphk1 and Sphk2, using Sphk2−/− renal fibroblasts treated with the Sphk1 inhibitor PF543, resulted in reduced HIF-2α and Epo compared to the untreated Sphk2−/− cells. Exogenous sphingosine (Sph) enhanced HIF-2α and Epo, and this was abolished by the combined treatment with the selective S1P1 and S1P3 antagonists NIBR-0213 and TY52156, suggesting that Sph was taken up by cells and converted to iS1P and exported to then act in an autocrine manner through S1P1 and S1P3. The upregulation of HIF-2α and Epo synthesis by Sphk2 knockdown was confirmed in the human hepatoma cell line Hep3B, which is well-established to upregulate Epo production under hypoxia. In summary, these data show that sphingolipids have diverse effects on Epo synthesis. While accumulation of intracellular Sph reduces Epo synthesis, iS1P will be exported to act through S1P1+3 to enhance Epo synthesis. Furthermore, these data suggest that selective inhibition of Sphk2 is an attractive new option to enhance Epo synthesis and thereby to reduce anemia development in chronic kidney disease.
Abstract
Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB). Recently, the local production of dopamine in inflamed joints of RA has been observed. Thus, in this project, we aimed to determine the implication of the neurotransmitter dopamine in the bone formation process in RA. Dopamine receptors (DR) in the human bone tissue of RA or osteoarthritis (OA) patients were examined by immunohistochemistry. DR in isolated human osteoblasts (OB) was analyzed by flow cytometry, and dopamine content was evaluated by ELISA. Osteoclasts (OC) were differentiated from the PBMCs of healthy controls (HC) and RA patients. Isolated cells were treated with specific dopamine agonists. The effect of dopamine on mineralization was evaluated by Alizarin red staining. Cytokine release in supernatants was measured by ELISA. Osteoclastogenesis was evaluated with TRAP staining. OC markers were analyzed via real-time PCR and bone resorption via staining of resorption pits with toluidine blue. All DR were observed in bone tissue, especially in the bone remodeling area. Isolated OB maintained DR expression, which allowed their study in vitro. Isolated OB expressed tyrosine hydroxylase, the rate-limiting enzyme for dopamine production, and contained dopamine. The activation of D2-like DR significantly increased bone mineralization in RA osteoblasts and increased osteoclastogenesis but did not alter the expression of OC markers nor bone resorption. DR were found in the bone remodeling area of human bone tissue and dopamine can be produced by osteoblasts themselves, thus suggesting a local autocrine/paracrine pathway of dopamine in the bone. D2-like DRs are responsible for bone mineralization in osteoblasts from RA patients without an increase in bone resorption, thus suggesting the D2-like DR pathway as a possible future therapeutic target to counteract bone resorption in arthritis
Purpose: (i) To examine the criterion taller-than-wide (TTW) for the sonographic assessment of thyroid nodules in areas of iodine deficiency in terms of frequency, anatomical distribution within the thyroid gland and risk of malignancy. (ii) To develop a model for nodule growth in the thyroid gland. Methods: German multicenter study consisting of two parts. In the prospective part, thyroid nodules were sonographically measured in all three dimensions, location within the thyroid gland and contact to a protrusion-like formation (horn) in the dorsal position of thyroid gland was noted. In addition, further sonographic features such as the composition, echogenity, margins and calcifications were investigated. All nodules from the prospective part were assessed for malignancy as part of clinical routine at the decision of the treating physician adhering to institutionally based algorithms. In the retrospective part, only nodules with fine needle aspiration and/or histology were included. The risk of malignancy in TTW nodules was determined by correlating them with cyotological and histological results. Results: Prospective part: out of 441 consecutively evaluated thyroid nodules, 6 were found to be malignant (1.4%, 95% CI 0.6–2.7%). Among the 74 TTW nodules (17%), 1 was malignant (1%, 95% CI 0–4%). TTW nodules were more often located in the dorsal half of the thyroid than non-TTW nodules (factor 2.3, p = 0.01, 95% CI 2.1–2.5) and more often located in close proximity to a horn than non-TTW nodules (factor 3.0, p = 0.01, 95% CI 2.4–3.8). Retrospective part: out of 1315 histologically and/or cytologically confirmed thyroid nodules, 163 TTW nodules were retrieved and retrospectively analyzed. A TTW nodule was 1.7 times more often benign when it was dorsal (95% CI 1.1–2.5) and 2.5 times more often benign when it was associated with a horn (95% CI 1.2–5.3). The overall probability of malignancy for TTW nodules was 38% (95% CI 30–46%) in this highly preselected patient group. Conclusion: TTW nodules are common in iodine deficient areas. They are often located in the dorsal half of the thyroid gland and are frequently associated with a dorsal protrusion-like formation (horn) of the thyroid. Obviously, the shape of benign nodules follows distinct anatomical preconditions within the thyroid gland. The frequency of TTW nodules and their predominant benignity can be explained by a pole concept of goiter growth. The difference between the low malignancy risk of TTW nodules found on a prospective basis and the high risk found retrospectively may be the result of a positive preselection in the latter.
Purpose: As the population ages, the incidence of rectal cancer among elderly patients is rising. Due to the risk of perioperative morbidity and mortality, alternative nonoperative treatment options have been explored in elderly and frail patients who are clinically inoperable or refuse surgery.
Methods: Here we present technical considerations and first clinical experience after treating a cohort of six rectal cancer patients (T1‑3, N0‑1, M0; UICC stage I-IIIB) with definitive external-beam radiation therapy (EBRT) followed by image-guided, endorectal high-dose-rate brachytherapy (HDR-BT). Patients were treated with 10–13 × 3 Gy EBRT followed by HDR-BT delivering 12–18 Gy in two or three fractions. Tumor response was evaluated using endoscopy and magnetic resonance imaging of the pelvis.
Results: Median age was 84 years. All patients completed EBRT and HDR-BT without any high-grade toxicity (> grade 2). One patient experienced rectal bleeding (grade 2) after 10 weeks. Four patients (67%) demonstrated clinical complete response (cCR) or near cCR, there was one partial response, and one residual tumor and hepatic metastasis 8 weeks after HDR-BT. The median follow-up time for all six patients is 42 weeks (range 8–60 weeks). Sustained cCR without evidence of local regrowth has been achieved in all four patients with initial (n)cCR to date.
Conclusion: Primary EBRT combined with HDR-BT is feasible and well tolerated with promising response rates in elderly and frail rectal cancer patients. The concept could be an integral part of a highly individualized and selective nonoperative treatment offered to patients who are not suitable for or refuse surgery.
The analysis of postmortem protein degradation has become of large interest for the estimation of the postmortem interval (PMI). Although several techniques have been published in recent years, protein degradation-based techniques still largely did not exceed basic research stages. Reasons include impractical and complex sampling procedures, as well as highly variable protocols in the literature, making it difficult to compare results. Following a three-step procedure, this study aimed to establish an easily replicable standardized procedure for sampling and processing, and further investigated the reliability and limitations for routine application. Initially, sampling and processing were optimized using a rat animal model. In a second step, the possible influences of sample handling and storage on postmortem protein degradation dynamics were assessed on a specifically developed human extracorporeal degradation model. Finally, the practical application was simulated by the collection of tissue in three European forensic institutes and an international transfer to our forensic laboratory, where the samples were processed and analyzed according to the established protocol.
Mesenchymal stromal/stem cells and their derivates are the most promising cell source for cell therapies in regenerative medicine. The application of extracellular vesicles (EVs) as cell-free therapeuticals requires particles with a maximum regenerative capability to enhance tissue and organ regeneration. The cargo of mRNA and microRNA (miR) in EVs after hypoxic preconditioning has not been extensively investigated. Therefore, the aim of our study was the characterization of mRNA and the miR loading of EVs. We further investigated the effects of the isolated EVs on renal tubular epithelial cells in vitro. We found 3131 transcripts to be significantly regulated upon hypoxia. Only 15 of these were downregulated, but 3116 were up-regulated. In addition, we found 190 small RNAs, 169 of these were miRs and 21 were piwi-interacting RNAs (piR). However, only 18 of the small RNAs were significantly altered, seven were miRs and 11 were piRs. Interestingly, all seven miRs were down-regulated after hypoxic pretreatment, whereas all 11 piRs were up-regulated. Gene ontology term enrichment and miR-target enrichment analysis of the mRNAs and miR were also performed in order to study the biological background. Finally, the therapeutic effect of EVs on human renal tubular epithelial cells was shown by the increased expression of three anti-inflammatory molecules after incubation with EVs from hypoxic pretreatment. In summary, our study demonstrates the altered mRNA and miR load in EVs after hypoxic preconditioning, and their anti-inflammatory effect on epithelial cells.
Background: The factors driving the late phase of COVID-19 are still poorly understood. However, autoimmunity is an evolving theme in COVID-19’s pathogenesis. Additionally, deregulation of human retroelements (RE) is found in many viral infections, and has also been reported in COVID-19.
Results: Unexpectedly, coronaviruses (CoV) – including SARS-CoV-2 – harbour many RE-identical sequences (up to 35 base pairs), and some of these sequences are part of SARS-CoV-2 epitopes associated to COVID-19 severity. Furthermore, RE are expressed in healthy controls and human cells and become deregulated after SARS-CoV-2 infection, showing mainly changes in long interspersed nuclear element (LINE1) expression, but also in endogenous retroviruses.
Conclusion: CoV and human RE share coding sequences, which are targeted by antibodies in COVID-19 and thus could induce an autoimmune loop by molecular mimicry.
Background: Safety, tolerability and efficacy of granulocyte colony-stimulating factor (G-CSF) for mobilization of hematopoietic stem and progenitor cells (HSPCs) from healthy donors have been conclusively demonstrated. This explicitly includes, albeit for smaller cohorts and shorter observation periods, biosimilar G-CSFs. HSPC donation is non-remunerated, its sole reward being “warm glow”, hence harm to donors must be avoided with maximal certitude. To ascertain, therefore, long-term physical and mental health effects of HSPC donation, a cohort of G-CSF mobilized donors was followed longitudinally.
Methods: We enrolled 245 healthy volunteers in this bi-centric long-term surveillance study. 244 healthy volunteers began mobilization with twice-daily Sandoz biosimilar filgrastim and 242 underwent apheresis after G-CSF mobilization. Physical and mental health were followed up over a period of 5-years using the validated SF-12 health questionnaire.
Results: Baseline physical and mental health of HSPC donors was markedly better than in a healthy reference population matched for ethnicity, sex and age. Physical, but not mental health was sharply diminished at the time of apheresis, likely due to side effects of biosimilar G-CSF, however had returned to pre-apheresis values by the next follow-up appointment after 6 months. Physical and mental health slightly deteriorated over time with kinetics reflecting the known effects of aging. Hence, superior physical and mental health compared to the general healthy non-donor population was maintained over time.
Conclusions: HSPC donors are of better overall physical and mental health than the average healthy non-donor. Superior well-being is maintained over time, supporting the favorable risk–benefit assessment of volunteer HSPC donation.
Trial registration National Clinical Trial NCT01766934
A webinar series that was organised by the Academy of Pharmaceutical Sciences Biopharmaceutics focus group in 2021 focused on the challenges of developing clinically relevant dissolution specifications (CRDSs) for oral drug products. Industrial scientists, together with regulatory and academic scientists, came together through a series of six webinars, to discuss progress in the field, emerging trends, and areas for continued collaboration and harmonisation. Each webinar also hosted a Q&A session where participants could discuss the shared topic and information. Although it was clear from the presentations and Q&A sessions that we continue to make progress in the field of CRDSs and the utility/success of PBBM, there is also a need to continue the momentum and dialogue between the industry and regulators. Five key areas were identified which require further discussion and harmonisation.
Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA.1 breakthrough infection in BNT162b2-vaccinated individuals resulted in strong neutralizing activity against Omicron BA.1, BA.2, and previous SARS-CoV-2 VOCs but not against the Omicron sublineages BA.4 and BA.5. BA.1 breakthrough infection induced a robust recall response, primarily expanding memory B (BMEM) cells against epitopes shared broadly among variants, rather than inducing BA.1-specific B cells. The vaccination-imprinted BMEM cell pool had sufficient plasticity to be remodeled by heterologous SARS-CoV-2 spike glycoprotein exposure. Whereas selective amplification of BMEM cells recognizing shared epitopes allows for effective neutralization of most variants that evade previously established immunity, susceptibility to escape by variants that acquire alterations at hitherto conserved sites may be heightened.
Around 20% of the American population have chronic pain and estimates in other Western countries report similar numbers. This represents a major challenge for global health care systems. Additional problems for the treatment of chronic and persistent pain are the comparably low efficacy of existing therapies, the failure to translate effects observed in preclinical pain models to human patients and related setbacks in clinical trials from previous attempts to develop novel analgesics. Drug repurposing offers an alternative approach to identify novel analgesics as it can bypass various steps of classical drug development. In recent years, several approved drugs were attributed analgesic properties. Here, we review available data and discuss recent findings suggesting that the approved drugs minocycline, fingolimod, pioglitazone, nilotinib, telmisartan, and others, which were originally developed for the treatment of different pathologies, can have analgesic, antihyperalgesic, or neuroprotective effects in preclinical and clinical models of inflammatory or neuropathic pain. For our analysis, we subdivide the drugs into substances that can target neuroinflammation or substances that can act on peripheral sensory neurons, and highlight the proposed mechanisms. Finally, we discuss the merits and challenges of drug repurposing for the development of novel analgesics.
Background: Bacterial burden as well as duration of bacteremia influence the outcome of patients with bloodstream infections. Promptly decreasing bacterial load in the blood by using extracorporeal devices in addition to anti-infective therapy has recently been explored. Preclinical studies with the Seraph® 100 Microbind® Affinity Blood Filter (Seraph® 100), which consists of heparin that is covalently bound to polymer beads, have demonstrated an effective binding of bacteria and viruses. Pathogens adhere to the heparin coated polymer beads in the adsorber as they would normally do to heparan sulfate on cell surfaces. Using this biomimetic principle, the Seraph® 100 could help to decrease bacterial burden in vivo.
Methods: This first in human, prospective, multicenter, non-randomized interventional study included patients with blood culture positive bloodstream infection and the need for kidney replacement therapy as an adjunctive treatment for bloodstream infections. We performed a single four-hour hemoperfusion treatment with the Seraph® 100 in conjunction with a dialysis procedure. Post procedure follow up was 14 days.
Results: Fifteen hemodialysis patients (3F/12 M, age 74.0 [68.0–78.5] years, dialysis vintage 28.0 [11.0–45.0] months) were enrolled. Seraph® 100 treatment started 66.4 [45.7–80.6] hours after the initial positive blood culture was drawn. During the treatment with the Seraph® 100 with a median blood flow of 285 [225–300] ml/min no device or treatment related adverse events were reported. Blood pressure and heart rate remained stable while peripheral oxygen saturation improved during the treatment from 98.0 [92.5–98.0] to 99.0 [98.0–99.5] %; p = 0.0184. Four patients still had positive blood culture at the start of Seraph® 100 treatment. In one patient blood cultures turned negative during treatment. The time to positivity (TTP) was increased between inflow and outflow blood cultures by 36 [− 7.2 to 96.3] minutes. However, overall TTP increase was not statistical significant.
Conclusions: Seraph® 100 treatment was well tolerated. Adding Seraph® 100 to antibiotics early in the course of bacteremia might result in a faster resolution of bloodstream infections, which has to be evaluated in further studies.
Whereas the clinical approach in pediatric cancer patients with febrile neutropenia is well established, data on non-neutropenic infectious episodes are limited. We therefore prospectively collected over a period of 4 years of data on all infectious complications in children treated for acute lymphoblastic or myeloid leukemia (ALL or AML) and non-Hodgkin lymphoma (NHL) at two major pediatric cancer centers. Infections were categorized as fever of unknown origin (FUO), and microbiologically or clinically documented infections. A total of 210 patients (median age 6 years; 142 ALL, 23 AML, 38 NHL, 7 leukemia relapse) experienced a total of 776 infectious episodes (571 during neutropenia, 205 without neutropenia). The distribution of FUO, microbiologically and clinically documented infections, did not significantly differ between neutropenic and non-neutropenic episodes. In contrast to neutropenic patients, corticosteroids did not have an impact on the infectious risk in non-neutropenic children. All but one bloodstream infection in non-neutropenic patients were due to Gram-positive pathogens. Three patients died in the context of non-neutropenic infectious episodes (mortality 1.4%). Our results well help to inform clinical practice guidelines in pediatric non-neutropenic cancer patients presenting with fever, in their attempt to safely restrict broad-spectrum antibiotics and improve the quality of life by decreasing hospitalization.
Background: To minimize the risk of disease transmission in cornea transplantation, donor screening for blood-derived viral infections is mandatory. Ideally, pre-mortem blood samples are used, but based on availability, cadaveric blood samples of cornea donors may also be used. However, serological and nucleic acid amplification tests (NATs) need to be validated for the use of cadaveric specimens.
Methods: Hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) 1/2, and Treponema pallidum (syphilis)-specific serological and/or NAT assays were validated on different platforms (Abbott Alinity i, Alinity m, Roche Cobas 6800, and Roche Cobas AmpliPrep/Cobas TaqMan (CAP/CTM)) using (un)spiked paired pre- and post-mortem cornea donor blood samples from the same individual (up to 23.83 h after death) of 28 individuals in accordance with the specifications of the German Federal Institute for Vaccines and Biomedicines (Paul-Ehrlich-Institut [PEI]). In addition, routinely HBV-, HCV- and HIV-PCR-negative tested post-mortem blood samples of 24 individuals were used to assess NAT specificity.
Results: For the majority of serological parameters on the Abbott Alinity i (HBsAg, anti-HBc, anti-HBs, anti-HCV, anti-HIV, anti-HTLV 1/2, and anti-Treponema pallidum), ratios of generated test results of (un)spiked paired pre- and post-mortem blood samples differed ≤25%, with an agreement of qualitative pre- and post-mortem test results ranging from 91.2 to 100%. For NAT parameters (HBV, HCV, and HIV) on the Cobas 6800, Alinity m, and CAP/CTM, no significant deviation in virus concentrations (factor >5) of spiked pre- and post-mortem blood samples could be observed. Ct-values of corresponding internal controls did also not differ significantly (>1.5 Ct-values). In addition, no false-positive test results were generated when specificity was assessed.
Conclusion: Overall, fluctuations of test results for serological and NAT parameters in pre- and post-mortem blood samples examined in this study, were only limited and within the range of what is also observed when routinely testing fresh patient specimens. We conclude that all examined assays are eligible for the screening of blood samples taken up to about 24 h after the occurrence of death.
Background and purpose: Impaired kidney function is associated with an increased risk of vascular events in acute stroke patients, when assessed by single measurements of estimated glomerular filtration rate (eGFR). It is unknown whether repeated measurements provide additional information for risk prediction.
Methods: The MonDAFIS (Systematic Monitoring for Detection of Atrial Fibrillation in Patients with Acute Ischemic Stroke) study randomly assigned 3465 acute ischemic stroke patients to either standard procedures or an additive Holter electrocardiogram. Baseline eGFR (CKD-EPI formula) were dichotomized into values of < versus ≥60 ml/min/1.73 m2. eGFR dynamics were classified based on two in-hospital values as “stable normal” (≥60 ml/min/1.73 m2), “increasing” (by at least 15% from baseline, second value ≥ 60 ml/min/1.73 m2), “decreasing” (by at least 15% from baseline of ≥60 ml/min/1.73 m2), and “stable decreased” (<60 ml/min/1.73 m2). The composite endpoint (stroke, major bleeding, myocardial infarction, all-cause death) was assessed after 24 months. We estimated hazard ratios in confounder-adjusted models.
Results: Estimated glomerular filtration rate at baseline was available in 2947 and a second value in 1623 patients. After adjusting for age, stroke severity, cardiovascular risk factors, and randomization, eGFR < 60 ml/min/1.73 m2 at baseline (hazard ratio [HR] = 2.2, 95% confidence interval [CI] = 1.40–3.54) as well as decreasing (HR = 1.79, 95% CI = 1.07–2.99) and stable decreased eGFR (HR = 1.64, 95% CI = 1.20–2.24) were independently associated with the composite endpoint. In addition, eGFR < 60 ml/min/1.732 at baseline (HR = 3.02, 95% CI = 1.51–6.10) and decreasing eGFR were associated with all-cause death (HR = 3.12, 95% CI = 1.63–5.98).
Conclusions: In addition to patients with low eGFR levels at baseline, also those with decreasing eGFR have increased risk for vascular events and death; hence, repeated estimates of eGFR might add relevant information to risk prediction.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) can show variable histological growth patterns and present remarkable overlap with T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL). Previous studies suggest that NLPHL histological variants represent progression forms of NLPHL and THRLBCL transformation in aggressive disease. Since molecular studies of both lymphomas are limited due to the low number of tumor cells, the present study aimed to learn if a better understanding of these lymphomas is possible via detailed measurements of nuclear and cell size features in 2D and 3D sections. Whereas no significant differences were visible in 2D analyses, a slightly increased nuclear volume and a significantly enlarged cell size were noted in 3D measurements of the tumor cells of THRLBCL in comparison to typical NLPHL cases. Interestingly, not only was the size of the tumor cells increased in THRLBCL but also the nuclear volume of concomitant T cells in the reactive infiltrate when compared with typical NLPHL. Particularly CD8+ T cells had frequent contacts to tumor cells of THRLBCL. However, the nuclear volume of B cells was comparable in all cases. These results clearly demonstrate that 3D tissue analyses are superior to conventional 2D analyses of histological sections. Furthermore, the results point to a strong activation of T cells in THRLBCL, representing a cytotoxic response against the tumor cells with unclear effectiveness, resulting in enhanced swelling of the tumor cell bodies and limiting proliferative potential. Further molecular studies combining 3D tissue analyses and molecular data will help to gain profound insight into these ill-defined cellular processes.
Purpose: Preoperative (neoadjuvant) chemoradiotherapy (CRT) and total mesorectal excision is the standard treatment for rectal cancer patients (UICC stage II/III). Up to one-third of patients treated with CRT achieve a pathological complete response (pCR). These patients could be spared from surgery and its associated morbidity and mortality, and assigned to a “watch and wait” strategy. However, reliably identifying pCR based on clinical or imaging parameters remains challenging.
Experimental design: We generated gene-expression profiles of 175 patients with locally advanced rectal cancer enrolled in the CAO/ARO/AIO-94 and -04 trials. One hundred and sixty-one samples were used for building, training and validating a predictor of pCR using a machine learning algorithm. The performance of the classifier was validated in three independent cohorts, comprising 76 patients from (i) the CAO/ARO/AIO-94 and -04 trials (n = 14), (ii) a publicly available dataset (n = 38) and (iii) in 24 prospectively collected samples from the TransValid A trial.
Results: A 21-transcript signature yielded the best classification of pCR in 161 patients (Sensitivity: 0.31; AUC: 0.81), when not allowing misclassification of non-complete-responders (False-positive rate = 0). The classifier remained robust when applied to three independent datasets (n = 76).
Conclusion: The classifier can identify >1/3 of rectal cancer patients with a pCR while never classifying patients with an incomplete response as having pCR. Importantly, we could validate this finding in three independent datasets, including a prospectively collected cohort. Therefore, this classifier could help select rectal cancer patients for a “watch and wait” strategy.
Translational relevance: Forgoing surgery with its associated side effects could be an option for rectal cancer patients if the prediction of a pathological complete response (pCR) after preoperative chemoradiotherapy would be possible. Based on gene-expression profiles of 161 patients a classifier was developed and validated in three independent datasets (n = 76), identifying over 1/3 of patients with pCR, while never misclassifying a non-complete-responder. Therefore, the classifier can identify patients suited for “watch and wait”.
Tightly regulated and cell-specific NADPH-oxidases (Nox) represent one of the major sources of reactive oxygen species (ROS) signaling molecules that are involved in tissue development and stem cell self-renewal. We have characterized the role of Nox4 in osteo-progenitors during postnatal bone development. Nox4 expression in bone and ROS generation were increased during early osteoblast differentiation and bone development. Stromal osteoblastic cell self-renewal, proliferation and ROS production were significantly lower in samples from whole-body Nox4 knockout mice (Nox4-/-) and conditional knockout (CKO) mice with depletion of Nox4 in the limb bud mesenchyme compared with those from control mice (Nox4fl/fl), but they were reversed after 9 passages. In both sexes, bone volume, trabecular number and bone mineral density were significantly lower in 3-week old CKO and Nox4-/- mice compared with Nox4fl/fl controls. This was reflected in serum levels of bone formation markers alkaline phosphatase (ALP) and procollagen 1 intact N-terminal propeptide (P1NP). However, under-developed bone formation in 3-week old CKO and Nox4-/- mice quickly caught up to levels of control mice by 6-week of age, remained no different at 13-week of age, and was reversed in 32-week old male mice. Osteoclastogenesis showed no differences among groups, however, CTX1 reflecting osteoclast activity was significantly higher in 3-week old male CKO and Nox4-/- mice compared with control mice, and significantly lower in 32-week old Nox4-/- mice compared with control mice. These data suggest that Nox4 expression and ROS signaling in bone and osteoblastic cells coordinately play an important role in osteoblast differentiation, proliferation and maturation.
The SARS-CoV-2 Omicron variant is currently causing a large number of infections in many countries. A number of antiviral agents are approved or in clinical testing for the treatment of COVID-19. Despite the high number of mutations in the Omicron variant, we here show that Omicron isolates display similar sensitivity to eight of the most important anti-SARS-CoV-2 drugs and drug candidates (including remdesivir, molnupiravir, and PF-07321332, the active compound in paxlovid), which is of timely relevance for the treatment of the increasing number of Omicron patients. Most importantly, we also found that the Omicron variant displays a reduced capability of antagonising the host cell interferon response. This provides a potential mechanistic explanation for the clinically observed reduced pathogenicity of Omicron variant viruses compared to Delta variant viruses.
Recently, we have shown that SARS-CoV-2 Omicron virus isolates are less effective at inhibiting the host cell interferon response than Delta viruses. Here, we present further evidence that reduced interferon-antagonising activity explains at least in part why Omicron variant infections are inherently less severe than infections with other SARS-CoV-2 variants. Most importantly, we here also show that Omicron variant viruses display enhanced sensitivity to interferon treatment, which makes interferons promising therapy candidates for Omicron patients, in particular in combination with other antiviral agents.
Background: Nearly all patients with newly diagnosed glioblastoma experience recurrence following standard-of-care radiotherapy (RT) + temozolomide (TMZ). The purpose of the phase III randomized CheckMate 548 study was to evaluate RT + TMZ combined with the immune checkpoint inhibitor nivolumab (NIVO) or placebo (PBO) in patients with newly diagnosed glioblastoma with methylated MGMT promoter (NCT02667587).
Methods: Patients (N = 716) were randomized 1:1 to NIVO [(240 mg every 2 weeks × 8, then 480 mg every 4 weeks) + RT (60 Gy over 6 weeks) + TMZ (75 mg/m2 once daily during RT, then 150-200 mg/m2 once daily on days 1-5 of every 28-day cycle × 6)] or PBO + RT + TMZ following the same regimen. The primary endpoints were progression-free survival (PFS) and overall survival (OS) in patients without baseline corticosteroids and in all randomized patients.
Results: As of December 22, 2020, median (m)PFS (blinded independent central review) was 10.6 months (95% CI, 8.9-11.8) with NIVO + RT + TMZ vs 10.3 months (95% CI, 9.7-12.5) with PBO + RT + TMZ (HR, 1.1; 95% CI, 0.9-1.3) and mOS was 28.9 months (95% CI, 24.4-31.6) vs 32.1 months (95% CI, 29.4-33.8), respectively (HR, 1.1; 95% CI, 0.9-1.3). In patients without baseline corticosteroids, mOS was 31.3 months (95% CI, 28.6-34.8) with NIVO + RT + TMZ vs 33.0 months (95% CI, 31.0-35.1) with PBO + RT + TMZ (HR, 1.1; 95% CI, 0.9-1.4). Grade 3/4 treatment-related adverse event rates were 52.4% vs 33.6%, respectively.
Conclusions: NIVO added to RT + TMZ did not improve survival in patients with newly diagnosed glioblastoma with methylated or indeterminate MGMT promoter. No new safety signals were observed.
Characteristics of critical incident reporting systems in primary care: an international survey
(2022)
Aim: The aim of the study was to support the development of future critical incident reporting systems (CIRS) in primary care by collecting information on existing systems. Our focus was on processes used to report and analyse incidents, as well as strategies used to overcome difficulties.
Methods: Based on literature from throughout the world, we identified existing CIRS in primary care. We developed a questionnaire and sent it to operators of a purposeful sample of 17 CIRS in primary care. We used cross-case analysis to compare the answers and pinpoint important similarities and differences in the CIRS in our sample.
Results: Ten CIRS operators filled out the questionnaire, and 9 systems met the inclusion criteria. The sample of CIRS came from 8 different countries and was rather heterogeneous. The reporting systems invited a broad range of professions to report, with some also including reports by patients. In most cases, reporting was voluntary and conducted via an online reporting form. Reports were analysed locally, centrally, or both. The various CIRS used interesting ideas to deal with barriers. Some, for example, used confidential reporting modes as a compromise between anonymity and the need for follow-up investigations, whereas others used smartphone applications and call centres to speed up the reporting process.
Conclusion: We found multiple CIRS that have operated in primary care for many years, have received a high number of reports and were largely developed in accordance with recommendations found in literature. Although primary care in Germany differs from other countries, these CIRS could serve as an inspiration for CIRS in German primary care.
Background: An essential step in any medical research project after identifying the research question is to determine if there are sufficient patients available for a study and where to find them. Pursuing digital feasibility queries on available patient data registries has proven to be an excellent way of reusing existing real-world data sources. To support multicentric research, these feasibility queries should be designed and implemented to run across multiple sites and securely access local data. Working across hospitals usually involves working with different data formats and vocabularies. Recently, the Fast Healthcare Interoperability Resources (FHIR) standard was developed by Health Level Seven to address this concern and describe patient data in a standardized format. The Medical Informatics Initiative in Germany has committed to this standard and created data integration centers, which convert existing data into the FHIR format at each hospital. This partially solves the interoperability problem; however, a distributed feasibility query platform for the FHIR standard is still missing.
Objective: This study described the design and implementation of the components involved in creating a cross-hospital feasibility query platform for researchers based on FHIR resources. This effort was part of a large COVID-19 data exchange platform and was designed to be scalable for a broad range of patient data.
Methods: We analyzed and designed the abstract components necessary for a distributed feasibility query. This included a user interface for creating the query, backend with an ontology and terminology service, middleware for query distribution, and FHIR feasibility query execution service.
Results: We implemented the components described in the Methods section. The resulting solution was distributed to 33 German university hospitals. The functionality of the comprehensive network infrastructure was demonstrated using a test data set based on the German Corona Consensus Data Set. A performance test using specifically created synthetic data revealed the applicability of our solution to data sets containing millions of FHIR resources. The solution can be easily deployed across hospitals and supports feasibility queries, combining multiple inclusion and exclusion criteria using standard Health Level Seven query languages such as Clinical Quality Language and FHIR Search. Developing a platform based on multiple microservices allowed us to create an extendable platform and support multiple Health Level Seven query languages and middleware components to allow integration with future directions of the Medical Informatics Initiative.
Conclusions: We designed and implemented a feasibility platform for distributed feasibility queries, which works directly on FHIR-formatted data and distributed it across 33 university hospitals in Germany. We showed that developing a feasibility platform directly on the FHIR standard is feasible.
The advancement of medical technology has led not only to an increase in life expectancy but also to a rise in aging-related diseases. Aging promotes metabolic disorders, in turn affecting cardiovascular health. Derailment of biological processes in the pancreas, liver, adipose tissue, and skeletal muscle impairs glucose and lipid metabolism, and mitochondrial function, triggering the development of diabetes and lipid-related disorders that inflict damage on cardiac and vascular tissues. Long noncoding RNAs (lncRNAs) regulate a wide range of biological process and are one of the key factors controlling metabolism and mitochondria. Here, we discuss the versatile function of lncRNAs involved in the metabolic regulation of glucose and lipid, and mitochondrial function, and how the dysregulation of lncRNAs induces the development of various metabolic disorders and their cardiovascular consequences.
Background: Trauma may be associated with significant to life-threatening blood loss, which in turn may increase the risk of complications and death, particularly in the absence of adequate treatment. Hydroxyethyl starch (HES) solutions are used for volume therapy to treat hypovolemia due to acute blood loss to maintain or re-establish hemodynamic stability with the ultimate goal to avoid organ hypoperfusion and cardiovascular collapse. The current study compares a 6% HES 130 solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) for volume replacement therapy in adult patients with traumatic injuries, as requested by the European Medicines Agency to gain more insights into the safety and efficacy of HES in the setting of trauma care.
Methods: TETHYS is a pragmatic, prospective, randomized, controlled, double-blind, multicenter, multinational trial performed in two parallel groups. Eligible consenting adults ≥ 18 years, with an estimated blood loss of ≥ 500 ml, and in whom initial surgery is deemed necessary within 24 h after blunt or penetrating trauma, will be randomized to receive intravenous treatment at an individualized dose with either a 6% HES 130, or an electrolyte solution, for a maximum of 24 h or until reaching the maximum daily dose of 30 ml/kg body weight, whatever occurs first. Sample size is estimated as 175 patients per group, 350 patients total (α = 0.025 one-tailed, power 1–β = 0.8). Composite primary endpoint evaluated in an exploratory manner will be 90-day mortality and 90-day renal failure, defined as AKIN stage ≥ 2, RIFLE injury/failure stage, or use of renal replacement therapy (RRT) during the first 3 months. Secondary efficacy and safety endpoints are fluid administration and balance, changes in vital signs and hemodynamic status, changes in laboratory parameters including renal function, coagulation, and inflammation biomarkers, incidence of adverse events during treatment period, hospital, and intensive care unit (ICU) length of stay, fitness for ICU or hospital discharge, and duration of mechanical ventilation and/or RRT.
Discussion: This pragmatic study will increase the evidence on safety and efficacy of 6% HES 130 for treatment of hypovolemia secondary to acute blood loss in trauma patients.
Trial registration:Registered in EudraCT, No.: 2016-002176-27 (21 April 2017) and ClinicalTrials.gov, ID: NCT03338218 (09 November 2017).
Background: Blood pressure is known to be increased in kidney donors following living-donor kidney transplantation. However, the physiological underpinnings of the blood-pressure increase following uninephrectomy remain unclear. We hypothesized that changes in sympathetic tone or in parasympathetic modulation of sinus node function are involved in the blood-pressure increase following experimental kidney-mass reduction.
Methods: C57BL6N mice (6 to 11 per group) subjected to sham surgery (controls) or uninephrectomy with or without a one-week course of sodium chloride-enriched, taurine-deficient diet were studied. Uninephrectomized mice treated with a subcutaneous infusion of angiotensin-II over a period of one week were positive controls. A transfemoral aortic catheter with telemetry unit was implanted, readings of heart-rate and blood-pressure were recorded. Powerspectral analysis of heart rate and systolic blood pressure was performed to gain surrogate parameters of sympathetictone and parasympathetic modulation of sinus node function. Baroreflex sensitivity of heart rate was determined from awake, unrestrained mice using spontaneous baroreflex gain technique.
Results: Systolic arterial blood pressure, heart rate and baroreflex sensitivity were not different in uninephrectomized mice when compared to controls. Parasympathetic modulation of sinus node function was less in uninephrectomized mice in comparison to controls. Uninephrectomized mice of the high-angiotensin-II model or of the high-salt and taurine-deficiency model had an increased systolic arterial blood pressure.
Conclusions: Uninephrectomy associated with less parasympathetic modulation of sinus node function. The combination of uninephrectomy, taurine-deficiency and high-salt intake led to arterial hypertension.
Nowadays, several options are available to treat patients with conductive or mixed hearing loss. Whenever surgical intervention is not possible or contra-indicated, and amplification by a conventional hearing device (e.g., behind-the-ear device) is not feasible, then implantable hearing devices are an indispensable next option. Implantable bone-conduction devices and middle-ear implants have advantages but also limitations concerning complexity/invasiveness of the surgery, medical complications, and effectiveness. To counsel the patient, the clinician should have a good overview of the options with regard to safety and reliability as well as unequivocal technical performance data. The present consensus document is the outcome of an extensive iterative process including ENT specialists, audiologists, health-policy scientists, and representatives/technicians of the main companies in this field. This document should provide a first framework for procedures and technical characterization to enhance effective communication between these stakeholders, improving health care.
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
(2022)
Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor cells. Activated SUMOylation allowed cancer cells to evade CD8+ T cell–mediated immunosurveillance by suppressing the MHC class I (MHC-I) antigen-processing and presentation machinery (APM). Loss of the MHC-I APM is a frequent cause of resistance to cancer immunotherapies, and the pharmacological inhibition of SUMOylation (SUMOi) resulted in reduced activity of the transcriptional repressor scaffold attachment factor B (SAFB) and induction of the MHC-I APM. Consequently, SUMOi enhanced the presentation of antigens and the susceptibility of tumor cells to CD8+ T cell–mediated killing. Importantly, SUMOi also triggered the activation of CD8+ T cells and thereby drove a feed-forward loop amplifying the specific antitumor immune response. In summary, we showed that activated SUMOylation allowed tumor cells to evade antitumor immunosurveillance, and we have expanded the understanding of SUMOi as a rational therapeutic strategy for enhancing the efficacy of cancer immunotherapies.
Although direct-acting antiviral medications effectively cure hepatitis C in most patients, sometimes treatment selects for resistant viruses, causing antiviral drugs to be either ineffective or only partially effective. Multidrug resistance is common in patients for whom DAA treatment fails. Older patients and patients with advanced liver diseases are more likely to select drug-resistant viruses. Collective efforts from international communities and governments are needed to develop an optimal approach to managing drug resistance and preventing the transmission of resistant viruses.
The induction of apoptosis is a direct way to eliminate tumor cells and improve cancer therapy. Apoptosis is tightly controlled by the balance of pro- and antiapoptotic Bcl-2 proteins. BH3 mimetics neutralize the antiapoptotic function of Bcl-2 proteins and are highly promising compounds inducing apoptosis in several cancer entities including pediatric malignancies. However, the clinical application of BH3 mimetics in solid tumors is impeded by the frequent resistance to single BH3 mimetics and the anticipated toxicity of high concentrations or combination treatments. One potential avenue to increase the potency of BH3 mimetics is the development of immune cell-based therapies to counteract the intrinsic apoptosis resistance of tumor cells and sensitize them to immune attack. Here, we describe spheroid cultures of pediatric cancer cells that can serve as models for drug testing. In these 3D models, we were able to demonstrate that activated allogeneic Natural Killer (NK) cells migrated into tumor spheroids and displayed cytotoxicity against a wide range of pediatric cancer spheroids, highlighting their potential as anti-tumor effector cells. Next, we investigated whether treatment of tumor spheroids with subtoxic concentrations of BH3 mimetics can increase the cytotoxicity of NK cells. Notably, the cytotoxic effects of NK cells were enhanced by the addition of BH3 mimetics. Treatment with either the Bcl-XL inhibitor A1331852 or the Mcl-1 inhibitor S63845 increased the cytotoxicity of NK cells and reduced spheroid size, while the Bcl-2 inhibitor ABT-199 had no effect on NK cell-mediated killing. Taken together, this is the first study to describe the combination of BH3 mimetics targeting Bcl-XL or Mcl-1 with NK cell-based immunotherapy, highlighting the potential of BH3 mimetics in immunotherapy.
Mutations of the isocitrate dehydrogenase-1 (IDH1) and IDH2 genes are among the most frequent alterations in acute myeloid leukemia (AML) and can be found in ∼20% of patients at diagnosis. Among 4930 patients (median age, 56 years; interquartile range, 45-66) with newly diagnosed, intensively treated AML, we identified IDH1 mutations in 423 (8.6%) and IDH2 mutations in 575 (11.7%). Overall, there were no differences in response rates or survival for patients with mutations in IDH1 or IDH2 compared with patients without mutated IDH1/2. However, distinct clinical and comutational phenotypes of the most common subtypes of IDH1/2 mutations could be associated with differences in outcome. IDH1-R132C was associated with increased age, lower white blood cell (WBC) count, less frequent comutation of NPM1 and FLT3 internal tandem mutation (ITD) as well as with lower rate of complete remission and a trend toward reduced overall survival (OS) compared with other IDH1 mutation variants and wild-type (WT) IDH1/2. In our analysis, IDH2-R172K was associated with significantly lower WBC count, more karyotype abnormalities, and less frequent comutations of NPM1 and/or FLT3-ITD. Among patients within the European LeukemiaNet 2017 intermediate- and adverse-risk groups, relapse-free survival and OS were significantly better for those with IDH2-R172K compared with WT IDH, providing evidence that AML with IDH2-R172K could be a distinct entity with a specific comutation pattern and favorable outcome. In summary, the presented data from a large cohort of patients with IDH1/2 mutated AML indicate novel and clinically relevant findings for the most common IDH mutation subtypes.
Objective: To assess the current medical practice in Europe regarding prenatal dexamethasone (Pdex) treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
Design and methods: A questionnaire was designed and distributed, including 17 questions collecting quantitative and qualitative data. Thirty-six medical centres from 14 European countries responded and 30 out of 36 centres were reference centres of the European Reference Network on Rare Endocrine Conditions, EndoERN.
Results: Pdex treatment is currently provided by 36% of the surveyed centres. The treatment is initiated by different specialties, that is paediatricians, endocrinologists, gynaecologists or geneticists. Regarding the starting point of Pdex, 23% stated to initiate therapy at 4–5 weeks postconception (wpc), 31% at 6 wpc and 46 % as early as pregnancy is confirmed and before 7 wpc at the latest. A dose of 20 µg/kg/day is used. Dose distribution among the centres varies from once to thrice daily. Prenatal diagnostics for treated cases are conducted in 72% of the responding centres. Cases treated per country and year vary between 0.5 and 8.25. Registries for long-term follow-up are only available at 46% of the centres that are using Pdex treatment. National registries are only available in Sweden and France.
Conclusions: This study reveals a high international variability and discrepancy in the use of Pdex treatment across Europe. It highlights the importance of a European cooperation initiative for a joint international prospective trial to establish evidence-based guidelines on prenatal diagnostics, treatment and follow-up of pregnancies at risk for CAH.
Myocardial injury as induced by myocardial infarction results in tissue ischemia, which critically incepts cardiomyocyte death. Endothelial cells play a crucial role in restoring oxygen and nutrient supply to the heart. Latest advances in single-cell multi-omics, together with genetic lineage tracing, reveal a transcriptional and phenotypical adaptation to the injured microenvironment, which includes alterations in metabolic, mesenchymal, hematopoietic and pro-inflammatory signatures. The extent of transition in mesenchymal or hematopoietic cell lineages is still debated, but it is clear that several of the adaptive phenotypical changes are transient and endothelial cells revert back to a naïve cell state after resolution of injury responses. This resilience of endothelial cells to acute stress responses is important for preventing chronic dysfunction. Here, we summarize how endothelial cells adjust to injury and how this dynamic response contributes to repair and regeneration. We will highlight intrinsic and microenvironmental factors that contribute to endothelial cell resilience and may be targetable to maintain a functionally active, healthy microcirculation.
Besides transcription, RNA decay accounts for a large proportion of regulated gene expression and is paramount for cellular functions. Classical RNA surveillance pathways, like nonsense-mediated decay (NMD), are also implicated in the turnover of non-mutant transcripts. Whereas numerous protein factors have been assigned to distinct RNA decay pathways, the contribution of long non-coding RNAs (lncRNAs) to RNA turnover remains unknown. Here we identify the lncRNA CALA as a potent regulator of RNA turnover in endothelial cells. We demonstrate that CALA forms cytoplasmic ribonucleoprotein complexes with G3BP1 and regulates endothelial cell functions. A detailed characterization of these G3BP1-positive complexes by mass spectrometry identifies UPF1 and numerous other NMD factors having cytoplasmic G3BP1-association that is CALA-dependent. Importantly, CALA silencing impairs degradation of NMD target transcripts, establishing CALA as a non-coding regulator of RNA steady-state levels in the endothelium.
Providing an interactive undergraduate elective on safety culture online – concept and evaluation
(2022)
Background: The COVID-19 pandemic has made it more difficult to maintain high quality in medical education. As online formats are often considered unsuitable, interactive workshops and seminars have particularly often been postponed or cancelled. To meet the challenge, we converted an existing interactive undergraduate elective on safety culture into an online event. In this article, we describe the conceptualization and evaluation of the elective.
Methods: The learning objectives of the safety culture elective remained unchanged, but the teaching methods were thoroughly revised and adapted to suit an online setting. The online elective was offered as a synchronous two-day course in winter semester 2020/21 during the “second wave” of the COVID-19 pandemic in Germany. At the end of each day, participating students evaluated the elective by completing an online survey. Items were rated on a six-point Likert scale. We used SPSS for data analysis.
Results: Twenty medical undergraduates completed the elective and rated it extremely positively (1.1 ± 0.2). Students regard safety culture as very important and felt the learning objectives had been achieved. Moreover, they were very satisfied with the design and content of the elective, and especially with interactive elements like role-play. Around 55% of participants would recommend continuing to offer the online elective after the pandemic.
Conclusions: It makes sense to offer undergraduate medical students online elective courses on safety culture, especially during a pandemic. The elective described here can serve as a best practice example of how to teach safety culture to undergraduates, especially when physical presence is unfeasible. Electives requiring a high degree of interaction can also function well online.
(1) Background: Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are biologically at high risk for the development of loco–regional recurrences after postoperative radiotherapy (PORT) but at intermediate risk according to clinical risk factors may benefit from additional concurrent chemotherapy. In this matched-pair study, we aimed to identify a corresponding predictive gene signature. (2) Methods: Gene expression analysis was performed on a multicenter retrospective cohort of 221 patients that were treated with postoperative radiochemotherapy (PORT-C) and 283 patients who were treated with PORT alone. Propensity score analysis was used to identify matched patient pairs from both cohorts. From differential gene expression analysis and Cox regression, a predictive gene signature was identified. (3) Results: 108 matched patient pairs were selected. We identified a 2-metagene signature that stratified patients into risk groups in both cohorts. The comparison of the high-risk patients between the two types of treatment showed higher loco–regional control (LRC) after treatment with PORT-C (p < 0.001), which was confirmed by a significant interaction term in Cox regression (p = 0.027), i.e., the 2-metagene signature was indicative for the type of treatment. (4) Conclusion: We have identified a novel gene signature that may be helpful to identify patients with high-risk HNSCC amongst those at intermediate clinical risk treated with PORT, who may benefit from additional concurrent chemotherapy.
Depressive symptoms in youth with ADHD: the role of impairments in cognitive emotion regulation
(2022)
Youth with attention-deficit/hyperactivity disorder (ADHD) are at increased risk to develop co-morbid depression. Identifying factors that contribute to depression risk may allow early intervention and prevention. Poor emotion regulation, which is common in adolescents, is a candidate risk factor. Impaired cognitive emotion regulation is a fundamental characteristic of depression and depression risk in the general population. However, little is known about cognitive emotion regulation in youth with ADHD and its link to depression and depression risk. Using explicit and implicit measures, this study assessed cognitive emotion regulation in youth with ADHD (N = 40) compared to demographically matched healthy controls (N = 40) and determined the association with depressive symptomatology. As explicit measure, we assessed the use of cognitive emotion regulation strategies via self-report. As implicit measure, performance in an ambiguous cue-conditioning task was assessed as indicator of affective bias in the processing of information. Compared to controls, patients reported more frequent use of maladaptive (i.e., self-blame, catastrophizing, and rumination) and less frequent use of adaptive (i.e., positive reappraisal) emotion regulation strategies. This pattern was associated with the severity of current depressive symptoms in patients. In the implicit measure of cognitive bias, there was no significant difference in response of patients and controls and no association with depression. Our findings point to depression-related alterations in the use of cognitive emotion regulation strategies in youth with ADHD. The study suggests those alterations as a candidate risk factor for ADHD-depression comorbidity that may be used for risk assessment and prevention strategies.
Purpose: To investigate the diagnostic performance of noise-optimized virtual monoenergetic images (VMI+) in dual-energy CT (DECT) of portal vein thrombosis (PVT) compared to standard reconstructions. Method: This retrospective, single-center study included 107 patients (68 men; mean age, 60.1 ± 10.7 years) with malignant or cirrhotic liver disease and suspected PVT who had undergone contrast-enhanced portal-phase DECT of the abdomen. Linearly blended (M_0.6) and virtual monoenergetic images were calculated using both standard VMI and noise-optimized VMI+ algorithms in 20 keV increments from 40 to 100 keV. Quantitative measurements were performed in the portal vein for objective contrast-to-noise ratio (CNR) calculation. The image series showing the greatest CNR were further assessed for subjective image quality and diagnostic accuracy of PVT detection by two blinded radiologists. Results: PVT was present in 38 subjects. VMI+ reconstructions at 40 keV revealed the best objective image quality (CNR, 9.6 ± 4.3) compared to all other image reconstructions (p < 0.01). In the standard VMI series, CNR peaked at 60 keV (CNR, 4.7 ± 2.1). Qualitative image parameters showed the highest image quality rating scores for the 60 keV VMI+ series (median, 4) (p ≤ 0.03). The greatest diagnostic accuracy for the diagnosis of PVT was found for the 40 keV VMI+ series (sensitivity, 96%; specificity, 96%) compared to M_0.6 images (sensitivity, 87%; specificity, 92%), 60 keV VMI (sensitivity, 87%; specificity, 97%), and 60 keV VMI+ reconstructions (sensitivity, 92%; specificity, 97%) (p ≤ 0.01). Conclusions: Low-keV VMI+ reconstructions resulted in significantly improved diagnostic performance for the detection of PVT compared to other DECT reconstruction algorithms.
Background: With the rise of single-cell RNA sequencing new bioinformatic tools have been developed to handle specific demands, such as quantifying unique molecular identifiers and correcting cell barcodes. Here, we benchmarked several datasets with the most common alignment tools for single-cell RNA sequencing data. We evaluated differences in the whitelisting, gene quantification, overall performance, and potential variations in clustering or detection of differentially expressed genes. We compared the tools Cell Ranger version 6, STARsolo, Kallisto, Alevin, and Alevin-fry on 3 published datasets for human and mouse, sequenced with different versions of the 10X sequencing protocol.
Results: Striking differences were observed in the overall runtime of the mappers. Besides that, Kallisto and Alevin showed variances in the number of valid cells and detected genes per cell. Kallisto reported the highest number of cells; however, we observed an overrepresentation of cells with low gene content and unknown cell type. Conversely, Alevin rarely reported such low-content cells. Further variations were detected in the set of expressed genes. While STARsolo, Cell Ranger 6, Alevin-fry, and Alevin produced similar gene sets, Kallisto detected additional genes from the Vmn and Olfr gene family, which are likely mapping artefacts. We also observed differences in the mitochondrial content of the resulting cells when comparing a prefiltered annotation set to the full annotation set that includes pseudogenes and other biotypes.
Conclusion: Overall, this study provides a detailed comparison of common single-cell RNA sequencing mappers and shows their specific properties on 10X Genomics data.
Targeted delivery of nucleic acids is gaining momentum due to improved efficacy, selectivity, increased circulation time and enhanced tissue retention in target cells. Using nucleic acid-based therapies previously undruggable targets have proven now to be amenable for treatment. Currently, several methods for preparing targeted or labelled delivery vehicles for nucleic acids are based on liposomal formulations. Lipid nanoparticles (LNPs) are structurally different from liposomes and these methods should therefore be evaluated before being translated to siRNA LNPs preparation protocols. Here, we describe a robust and facile method for the preparation of targeted or fluorescently labelled siRNA LNPs. Using a copper free strain-promoted azide-alkyne cycloaddition (SPAAC) we demonstrate that post-insertion of ligand-lipid conjugates into preformed LNPs is superior to direct-surface modification because it preserves the physicochemical parameters of the LNPs. We found that the time point of solvent removal by dialysis is critical and affects the hydrodynamic diameter of the LNPs; post-insertion after dialysis shows the smallest increase in hydrodynamic diameter and polydispersity index (PDI). The post-insertion of ligand-lipid conjugates also proceeded with rapid kinetics and high efficacy over a wide temperature range. Using this optimised protocol, we generated siRNA LNPs containing both targeting and fluorescent tracking ligands allowing us to monitor siRNA LNP uptake kinetics in dependence of the targeting ligand. In aggregate, we describe a robust approach for the generation of targeted and labelled siRNA LNPs that allows their controlled and facile decoration with ligand combinations.
Background & Aims: Liver fibrosis arises from long-term chronic liver injury, accompanied by an accelerated wound healing response with interstitial accumulation of extracellular matrix (ECM). Activated hepatic stellate cells (HSC) are the main source for ECM production. MicroRNA29a (miR-29a) is a crucial antifibrotic miRNA that is repressed during fibrosis, resulting in up-regulation of collagen synthesis.
Methods; Intracellular and extracellular miRNA levels of primary and immortalized myofibroblastic HSC in response to profibrogenic stimulation by transforming growth factor β (TGFβ) or platelet-derived growth factor-BB (PDGF-BB) or upon inhibition of vesicular transport and autophagy processes were determined by quantitative polymerase chain reaction. Autophagy flux was studied by electron microscopy, flow cytometry, immunoblotting, and immunocytochemistry. Hepatic and serum miR-29a levels were quantified by using both liver tissue and serum samples from a cohort of chronic hepatitis C virus patients and a murine CCl4 induced liver fibrosis model.
Results: In our study, we show that TGFβ and PDGF-BB resulted in decrease of intracellular miR-29a and a pronounced increase of vesicular miR-29a release into the supernatant. Strikingly, miR-29a vesicular release was accompanied by enhanced autophagic activity and up-regulation of the autophagy marker protein LC3. Moreover, autophagy inhibition strongly prevented miR-29a secretion and repressed its targets’ expression such as Col1A1. Consistently, hepatic miR-29a loss and increased LC3 expression in myofibroblastic HSC were associated with increased serum miR-29a levels in CCl4-treated murine liver fibrosis and specimens of hepatitis C virus patients with chronic liver disease.
Conclusions: We provide evidence that activation-associated autophagy in HSC induces release of miR-29a, whereas inhibition of autophagy represses fibrogenic gene expression in part through attenuated miR-29a secretion.
Background_ Postural control is associated with fall risk. Patients with rheumatoid arthritis (RA) have a higher risk to fall than healthy subjects. The objective of this study was to identify associations between variables of postural control with prospective falls in patients with RA.
Methods: For the baseline, the balance performance of 289 men and women with RA, ages 24–85 years, was evaluated by SPPB, FICSIT-4 and Romberg tests. Postural sway for Romberg, semitandem, tandem and one-leg stands were measured with the Leonardo Mechanograph®. Self-reported disability was assessed using the Health Assessment Questionnaire (HAQ) and the Activity-specific Balance Confidence Scale (ABC-scale). Falls were reported in quarterly reports over a year. Univariate and multiple logistic regression analysis were used to explore any associations with falling. Receiver-operating characteristics were determined, and the area under the curve is reported.
Results`A total of 238 subjects completed the 1-year follow-up, 48 (20.2%) experienced at least one fall during the observational period. Age (OR = 1.04, CI 1.01–1.07), HAQ (OR = 1.62, 1.1–2.38), FICSIT-4 scoring 0–4 (OR = 2.38, 1.13–5.0), and one-leg standing (OR = 2.14, 1.06–4.31) showed significant associations with falls. With regard to the SPPB and ABC-scale, no statistically significant associations with falls were found. The quartiles containing the worst results of medio-lateral sway of Romberg (OR = 2.63, CI 1.03–6.69), total sway of semitandem (OR = 3.07, CI 1.10–8.57) and tandem (OR = 2.86, CI 1.06–7.69), and area of sway of semitandem (OR = 2.80, CI 1.11–7.08) stands were associated with falls.
Conclusions: The assessment of a one-leg stand seems to be a good screening tool to discriminate between high and low risk of falls in RA patients in clinical practice. A low FICSIT-4 score and several sway parameters are important predictors of falls.
Background & Aims: Elimination of chronic HBV/HDV infection remains a major global health challenge. Targeting excessive hepatitis B surface antigen (HBsAg) release may provide an interesting window of opportunity to break immune tolerance and to achieve a functional cure using additional antivirals.
Methods: We evaluated a HBsAg-specific human monoclonal antibody, as part of either a prophylactic or therapeutic strategy, against HBV/HDV infection in cell culture models and in human-liver chimeric mice. To assess prophylactic efficacy, mice were passively immunized prior to infection with HBV or HBV/HDV (coinfection and superinfection setting). Therapeutic efficacy was assessed in HBV and HBV/HDV-coinfected mice receiving 4 weeks of treatment. Viral parameters (HBV DNA, HDV RNA and HBsAg) were assessed in mouse plasma.
Results: The antibody could effectively prevent HBV/HDV infection in a dose-dependent manner with IC50 values of ∼3.5 ng/ml. Passive immunization showed complete protection of mice from both HBV and HBV/HDV coinfection. Moreover, HDV superinfection was either completely prevented or at least attenuated in HBV-infected mice. Finally, antibody treatment in mice with established HBV/HDV infection resulted in a significant decline in viremia and a concomitant drop in on-treatment HBsAg, with a moderate viral rebound following treatment cessation.
Conclusion: We present data on a valuable antibody candidate that could complement other antivirals in strategies aimed at achieving functional cure of chronic HBV and HDV infection.
Impact and implications: Patients chronically infected with HBV may eventually develop liver cancer and are at great risk of being superinfected with HDV, which worsens and accelerates disease progression. Unfortunately, current treatments can rarely eliminate both viruses from chronically infected patients. In this study, we present data on a novel antibody that is able to prevent chronic HBV/HDV infection in a mouse model with a humanized liver. Moreover, antibody treatment of HBV/HDV-infected mice strongly diminishes viral loads during therapy. This antibody is a valuable candidate for further clinical development.
Results of a prospective non-interventional post-authorization safety study of idelalisib in Germany
(2022)
Background: In pivotal studies, idelalisib demonstrated remarkable efficacy and manageable tolerability in patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). This prospective, multicenter, non-interventional post-authorization study assessed the characteristics, clinical management, and outcome of CLL and FL patients receiving idelalisib in routine clinical practice in Germany.
Patients: Observational study in CLL and FL patients treated with idelalisib between September 2015 and December 2020.
Results: A total of 147 patients with CLL and FL were included with a median age of 75 and 71 years, respectively. More than 80% of patients presented with comorbidity and many CLL patients with documented high-risk genetic features, including del(17p)/TP53 mutation or unmutated IGHV. The median progression-free survival (PFS) and overall survival (OS) were not reached in the CLL cohort irrespective of del(17p)/TP53 or unmutated IGHV. The estimated 6-month PFS and OS rates in CLL were 82% and 92%. The estimated 6-month PFS and OS rates for FL were 32.2% and 77.2%. Overall response rates in the CLL and FL cohorts were 70.4% and 36.4%, with the presence of high-risk genetics having no negative impact. No unexpected adverse events were observed. Most frequently reported adverse drug reactions (ADRs) were diarrhea, nausea, pneumonia, rash, and fatigue.
Conclusion: This real-world study shows that idelalisib is an effective therapy for CLL and FL, regardless of age and high-risk genetic features, consistent with results from previous clinical trials. Collected safety data and the pattern of ADRs reflect those from previous studies.
The endoplasmic reticulum (ER) is the largest cellular organelle that undergoes constant turnover upon diverse functional demands and cellular signals. Removal of nonfunctional or superfluous subdomains is balanced by the parallel expansion and formation of ER membranes, leading to the dynamic exchange of ER components. In recent years, selective autophagy of the ER, termed ER-phagy, has emerged as a predominant process involved in ER degradation and maintenance of ER homeostasis. Identification of multiple ER-phagy receptors, many with additional ER-shaping functions, paved the way for our molecular understanding of ER turnover in different cells and organs. In this review, we describe the molecular principles underling the physiological functions of ER-phagy in maintaining ER homeostasis via receptor-mediated macroautophagy and elaborate current focus points of the field.
Purpose: Recent advances in the treatment algorithm of locally advanced rectal cancer (LARC) have significantly improved complete response (CR) rates and disease-free survival (DFS), but therapy resistance, with its substantial impact on outcomes and survival, remains a major challenge. Our group has recently unraveled a critical role of interleukin-1α (IL-1α) signaling in activating inflammatory cancer-associated fibroblasts (iCAFs) and mediating radiation-induced senescence, extracellular matrix (ECM) accumulation, and ultimately therapy resistance. We here summarize the recently initiated ACO/ARO/AIO-21 phase I trial, testing the IL-1 receptor antagonist (IL-1 RA) anakinra in combination with fluoropyrimidine-based chemoradiotherapy (CRT) for advanced rectal cancer.
Methods/Design: The ACO/ARO/AIO-21 is an investigator-driven, prospective, open-labeled phase I drug-repurposing trial assessing the maximum tolerated dose (MTD) of capecitabine administered concurrently to standard preoperative radiotherapy (45 Gy in 25 fractions followed by 9 Gy boost in 5 fractions) in combination with fixed doses of the IL-1RA anakinra (100 mg, days −10 to 40). Capecitabine will be administered using a 3 + 3 dose-escalation design (500 mg/m2 bid; 650 mg/m2 bid; 825 mg/m2 bid, respectively) from day 1 to day 40. Response assessment including digital rectal examination (DRE), endoscopy and pelvic magnetic resonance imaging (MRI) is scheduled 10 weeks after completion of CRT. For patients achieving clinical complete response (cCR), primary non-operative management is provided. In case of non-cCR immediate total mesorectal excision (TME) will be performed. Primary endpoint of this phase I trial is the MTD of capecitabine.
Discussion: Based on extensive preclinical research, the ACO/ARO/AIO-21 phase I trial will assess whether the IL-1RA anakinra can be safely combined with fluoropyrimidine-based CRT in rectal cancer. It will further explore the potential of IL-1 inhibition to overcome therapy resistance and improve response rates. A comprehensive translational research program will expand our understanding from a clinical perspective and may help translate the results into a randomized phase II trial.
Background: Postoperative complication rates using 3D visualization are rarely reported. The primary aim of our study is to detect a possible advantage of using 3D on postoperative complication rates in a real-world setting.
Method: With a sample size calculation for a medium effect size difference that 3D reduces significantly postoperative complications, data of 287 patients with 3D visualization and 832 with 2D procedure were screened. The groups underwent an exact propensity score-matching to be comparable. Comprehensive complication index (CCI) for every procedure was calculated and Operation Time was determined.
Results: Including 1078 patients in the study, 213 exact propensity score-matched pairs could finally be established. Concerning overall CCI (3D: 5.70 ± 13.63 vs. 2D: 3.37 ± 9.89; p = 0.076) and operation time (3D: 103.98 ± 93.26 min vs. 2D: 88.60 ±6 9.32 min; p = 0.2569) there was no significant difference between the groups.
Conclusion: Our study shows no advantage of 3D over 2D laparoscopy regarding postoperative complications in a real-world setting, the second endpoint operation time, too, was not influenced by 3D overall.
Keywords: 3D laparoscopy; Comprehensive complication index; Propensity score matching
ER remodeling via ER-phagy
(2022)
The endoplasmic reticulum (ER) is a hotspot for many essential cellular functions. The ER membrane is highly dynamic, which affects many cellular processes that take place within the ER. One such process is ER-phagy, a selective degradation of ER fragments (including membranes and luminal content), which serves to preserve the size of ER while adapting its morphology under basal and stress conditions. In order to be degraded, the ER undergoes selective fragmentation facilitated by specialized ER-shaping proteins that also act as ER-phagy receptors. Their ability to sense and induce membrane curvature, as well as to bridge the ER with autophagy machinery, allows for a successful ER fragmentation and delivery of these fragments to the lysosome for degradation and recycling. In this review, we provide insights into ER-phagy from the perspective of membrane remodeling. We highlight the importance of ER membrane dynamics during ER-phagy and emphasize how its dysregulation reflects on human physiology and pathology.